Cardax (CDXI) S-1/A 22 Nov 19 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2019
Document And Entity Information
Entity Registrant Name	CARDAX, INC.
Entity Central Index Key	0001544238
Document Type	S-1/A
Document Period End Date	Sep. 30, 2019
Amendment Flag	true
Amendment Description	Amendment No. 2
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash	$ 7,470	$ 243,753	$ 2,236,837
Accounts receivable	185,419	157,082	37,243
Inventories	1,307,727	1,480,380	340,425
Deposits and other assets	119,066	119,066	90,831
Prepaid expenses	45,096	24,083	22,838
Total current assets	1,664,778	2,024,364	2,728,174
PROPERTY AND EQUIPMENT, net			1,901
INTANGIBLE ASSETS, net	427,621	434,534	426,610
RIGHT TO USE LEASED ASSETS	22,015
TOTAL ASSETS	2,114,414	2,458,898	3,156,685
CURRENT LIABILITIES
Accrued payroll and payroll related expenses, current portion	3,471,812	3,428,011	3,404,610
Accounts payable and accrued expenses	1,706,117	1,996,097	603,391
Fees payable to directors	418,546	418,546	418,546
Accrued separation costs, current portion	9,000	9,000
Current portion of related party notes payable	575,000
Related party convertible note payable	537,848
Convertible notes payable, net of discount	256,698
Employee settlement	50,000	50,000	50,000
Lease liability, current portion	17,129
Derivative liability on convertible note payable	246,414
Total current liabilities	7,288,564	5,901,654	4,476,547
NON-CURRENT LIABILITIES
Related party notes payable, net of current portion	1,000,000
Accrued separation costs, less current portion	85,885	92,635	85,615
Lease liability, less current portion	4,886
Total non-current liabilities	1,090,771	92,635
COMMITMENTS AND CONTINGENCIES
Total liabilities	8,379,335	5,994,289	4,562,162
STOCKHOLDERS' DEFICIT
Preferred Stock, value
Common stock, value	137,262	133,889	122,675
Additional paid-in-capital	59,191,875	58,274,038	56,401,069
Deferred compensation			(10,125)
Accumulated deficit	(65,594,058)	(61,943,318)	(57,919,096)
Total stockholders' deficit	(6,264,921)	(3,535,391)	(1,405,477)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 2,114,414	$ 2,458,898	$ 3,156,685

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000	50,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000	400,000,000
Common stock, shares issued	137,261,594	133,888,573	122,674,516
Common stock, shares outstanding	137,261,594	133,888,573	122,674,516

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
REVENUES, net	$ 229,142	$ 549,540	$ 439,505	$ 1,134,899	$ 1,510,875	$ 610,323
COST OF GOODS SOLD	120,818	240,152	254,479	521,353	699,852	274,707
GROSS PROFIT	108,324	309,388	185,026	613,546	811,023	335,616
OPERATING EXPENSES:
Salaries and wages	387,636	387,119	1,177,362	1,202,576	1,591,949	830,922
Professional fees	375,298	225,875	817,546	637,042	797,833	435,749
Selling, general, and administrative expenses	206,042	350,630	731,487	1,168,747	1,493,819	702,168
Stock based compensation	175,712	180,562	534,774	443,249	650,271	242,146
Research and development	145,273	86,115	250,141	214,093	269,077	97,479
Depreciation and amortization	10,074	6,718	29,102	23,853	30,569	29,422
Total operating expenses	1,300,035	1,237,019	3,540,412	3,689,560	4,833,518	2,337,886
Loss from operations	(1,191,711)	(927,631)	(3,355,386)	(3,076,014)	(4,022,495)	(2,002,270)
OTHER INCOME (EXPENSE):
Interest income	3	7	5	1,941	1,944	3,320
Other income				556	556	17,253
Change in fair value of derivative liability	(20,524)		(3,139)
Loss on abandonment of patents	(36,205)		(36,205)
Interest expense	(185,189)	(1,264)	(256,015)	(3,356)	(4,227)	(3,537)
Total other (expense) income, net	(241,915)	(1,257)	(295,354)	(859)	(1,727)	17,036
Loss before the provision for income taxes	(1,433,626)	(928,888)	(3,650,740)	(3,076,873)	(4,024,222)	(1,985,234)
PROVISION FOR INCOME TAXES
NET LOSS	$ (1,433,626)	$ (928,888)	$ (3,650,740)	$ (3,076,873)	$ (4,024,222)	$ (1,985,234)
NET LOSS PER SHARE
Basic	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.03)	$ (0.02)
Diluted	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.03)	$ (0.02)
SHARES USED IN CALCULATION OF NET LOSS PER SHARE
Basic	136,640,761	130,083,598	135,516,490	125,271,516	127,304,856	99,951,385
Diluted	136,640,761	130,083,598	135,516,490	125,271,516	127,304,856	99,951,385

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholder Deficit - USD ($)	Common Stock [Member]	Additional Paid-In-Capital [Member]	Deferred Compensation [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2016	$ 85,069	$ 51,963,269		$ (55,933,862)	$ (3,885,524)
Balance, shares at Dec. 31, 2016	85,068,709
Common stock grants to independent directors	$ 793	149,207			150,000
Common stock grants to independent directors, shares	793,025
Common stock issuance to institutional investor	$ 568	59,432			60,000
Common stock issuance to institutional investor, shares	567,644
Restricted stock issuances	$ 34,108	4,044,327			4,078,435
Restricted stock issuances, shares	34,107,883
Restricted stock issuance to a broker for fees	$ 559	44,141			44,700
Restricted stock issuance to a broker for fees, shares	558,750
Stock option exercises - cashless	$ 645	(645)
Stock option exercises - cashless, shares	645,288				770,000
Warrant exercise	$ 733	39,267			$ 40,000
Warrant exercise, shares	733,217
Deferred compensation	$ 200	40,300	(10,125)		30,375
Deferred compensation, shares	200,000
Stock based compensation - options		61,771			61,771
Net loss				(1,985,234)	(1,985,234)
Balance at Dec. 31, 2017	$ 122,675	56,401,069	(10,125)	(57,919,096)	(1,405,477)
Balance, shares at Dec. 31, 2017	122,674,516
Common stock grants to independent directors	$ 907	199,093			200,000
Common stock grants to independent directors, shares	906,774
Stock option exercises - cashless	$ 157	(157)
Stock option exercises - cashless, shares	156,997
Deferred compensation			10,125		10,125
Deferred compensation, shares
Cardax 2018 Warrant Exchange Offering, net	$ 9,600	1,234,437			1,244,037
Cardax 2018 Warrant Exchange Offering, net, shares	9,600,286
Stock based compensation - options		233,124			233,124
Net loss				(3,076,873)	(3,076,873)
Balance at Sep. 30, 2018	$ 133,339	58,067,566		(60,995,969)	(2,795,064)
Balance, shares at Sep. 30, 2018	133,338,573
Balance at Dec. 31, 2017	$ 122,675	56,401,069	(10,125)	(57,919,096)	(1,405,477)
Balance, shares at Dec. 31, 2017	122,674,516
Common stock grants to independent directors	$ 1,345	286,155			287,500
Common stock grants to independent directors, shares	1,344,274
Stock option exercises - cashless	$ 157	(157)
Stock option exercises - cashless, shares	156,997				200,000
Deferred compensation			10,125		$ 10,125
Deferred compensation, shares
Cardax 2018 Warrant Exchange Offering, net	$ 9,600	1,234,437			1,244,037
Cardax 2018 Warrant Exchange Offering, net, shares	9,600,286
Stock based compensation - options		330,146			330,146
Common stock grant to service providers	$ 112	22,388			22,500
Common stock grant to service providers, shares	112,500
Net loss				(4,024,222)	(4,024,222)
Balance at Dec. 31, 2018	$ 133,889	58,274,038		(61,943,318)	(3,535,391)
Balance, shares at Dec. 31, 2018	133,888,573
Balance at Jun. 30, 2018	$ 123,301	56,653,005		(60,067,081)	(3,290,775)
Balance, shares at Jun. 30, 2018	123,300,787
Common stock grants to independent directors	$ 438	87,062			87,500
Common stock grants to independent directors, shares	437,500
Deferred compensation
Deferred compensation, shares
Cardax 2018 Warrant Exchange Offering, net	$ 9,600	1,234,437			1,244,037
Cardax 2018 Warrant Exchange Offering, net, shares	9,600,286
Stock based compensation - options		93,062			93,062
Net loss				(928,888)	(928,888)
Balance at Sep. 30, 2018	$ 133,339	58,067,566		(60,995,969)	(2,795,064)
Balance, shares at Sep. 30, 2018	133,338,573
Balance at Dec. 31, 2018	$ 133,889	58,274,038		(61,943,318)	(3,535,391)
Balance, shares at Dec. 31, 2018	133,888,573
Common stock grants to independent directors	$ 1,627	260,873			262,500
Common stock grants to independent directors, shares	1,627,191
Restricted stock issuances	$ 1,633	243,367			$ 245,000
Restricted stock issuances, shares	1,633,330
Stock option exercises - cashless, shares
Stock based compensation - options		257,875			$ 257,875
Common stock grant to service providers	$ 113	14,287			14,400
Common stock grant to service providers, shares	112,500
Issuance of warrants attached to a convertible note		141,435			141,435
Net loss				(3,650,740)	(3,650,740)
Balance at Sep. 30, 2019	$ 137,262	59,191,875		(65,594,058)	(6,264,921)
Balance, shares at Sep. 30, 2019	137,261,594
Balance at Jun. 30, 2019	$ 136,641	58,908,648		(64,160,432)	(5,115,143)
Balance, shares at Jun. 30, 2019	136,640,761
Common stock grants to independent directors	$ 583	86,917			87,500
Common stock grants to independent directors, shares	583,333
Stock based compensation - options		84,875			84,875
Common stock grant to service providers	$ 38	3,300			3,338
Common stock grant to service providers, shares	37,500
Issuance of warrants attached to a convertible note		108,135			108,135
Net loss				(1,433,626)	(1,433,626)
Balance at Sep. 30, 2019	$ 137,262	$ 59,191,875		$ (65,594,058)	$ (6,264,921)
Balance, shares at Sep. 30, 2019	137,261,594

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,433,626)	$ (928,888)	$ (3,650,740)	$ (3,076,873)	$ (4,024,222)	$ (1,985,234)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	10,074	6,718	29,102	23,853	30,569	29,422
Amortization of debt discount			129,256
Stock based compensation	175,712	180,562	534,774	443,249	650,271	242,146
Bad debt expense on note receivable and accrued interest				89,933	89,933
Loss on abandonment of patents	36,205		36,205
Change in fair value of derivative liability	20,524		3,139
Changes in assets and liabilities:
Accounts receivable			32,333	(193,168)	181,960	(37,243)
Inventories			172,653	14,251	97,736	(329,598)
Deposits and other assets				(118,168)	(118,168)	32,045
Prepaid expenses			(21,013)	(1,214)	(1,245)	(2,919)
Accrued payroll and payroll related expenses			43,801	55,230	39,421	(20,239)
Accounts payable and accrued expenses			(350,650)	50,752	(146,784)	(9,003)
Accrued separation costs			(6,750)
Net cash used in operating activities			(3,047,889)	(2,712,155)	(3,200,528)	(2,080,623)
CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in intangible assets			(58,394)	(30,483)	(36,593)	(19,408)
Net cash used in investing activities			(58,394)	(30,483)	(36,593)	(19,408)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuances of related party notes payable			1,575,000
Proceeds from the issuance of a related party convertible note payable			750,000
Proceeds from the issuances of convertible notes payable			300,000
Proceeds from the issuance of common stock			245,000	704,375	1,244,037	4,138,435
Proceeds from the exercise of warrants						40,000
Net cash provided by financing activities			2,870,000	704,375	1,244,037	4,178,435
NET DECREASE IN CASH			(236,283)	(2,038,263)	(1,993,084)	2,078,404
BEGINNING OF THE PERIOD			243,753	2,236,837	2,236,837	158,433
END OF THE PERIOD	$ 7,470	$ 198,574	7,470	198,574	243,753	2,236,837
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest			13,937	3,356	4,227	3,537
Cash paid for income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Discount recognized on notes payable at issuance			384,710
Conversion of accounts payable into restricted stock						44,700
Settlement of receivables with payables			60,670	221,814	301,799
Purchases of inventory in accounts payable					$ 1,237,691
Right to use assets funded through leases			$ 22,015	$ 539,662

Company Background

Company Background	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Company Background	NOTE 1 – COMPANY BACKGROUND The Company’s predecessor, Cardax Pharmaceuticals, Inc. (“Holdings”), was incorporated in the State of Delaware on March 23, 2006. Cardax, Inc. (the “Company”) (OTCQB:CDXI) is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. The Company also has a commercial business unit that markets dietary supplements for inflammatory health. CDX-101, the Company’s astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. The Company’s pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. ZanthoSyn® is a physician recommended astaxanthin dietary supplement for inflammatory health. The Company sells ZanthoSyn® primarily through wholesale and e-commerce channels. The safety and efficacy of the Company’s products have not been directly evaluated in clinical trials or confirmed by the FDA. Going concern matters The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company incurred net losses of $1,433,626 and $3,650,740 for the three and nine-months ended September 30, 2019, respectively, and incurred net losses of $928,888 and $3,076,873 for the three and nine-months ended September 30, 2018, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $65,594,058 as of September 30, 2019, and has had negative cash flows from operating activities since inception. The Company expects that its marketing program for ZanthoSyn® will continue to focus on outreach to physicians, healthcare professionals, retail personnel, and consumers, and anticipates further losses in the development of its consumer business. The Company also plans to advance the research and development of its pharmaceutical candidates and anticipates further losses in the development of its pharmaceutical business. As a result of these and other factors, management has determined there is substantial doubt about the Company’s ability to continue as a going concern. During the nine-months ended September 30, 2019, the Company raised additional capital to carry out its business plan. As part of the Company’s efforts, it raised an additional $245,000 in equity from existing stockholders and $2,625,000 in gross proceeds from debt, including $2,325,000 from related parties. On August 14, 2019, the Company filed a registration statement on Form S-1 for a proposed $15 million public offering of common stock and warrants. The Company intends to use the proceeds from the proposed public offering primarily to fund pharmaceutical development and its operations. The Company’s continued ability to raise additional capital through future equity and debt securities issuances is unknown. Obtaining additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.	NOTE 1 – COMPANY BACKGROUND The Company’s predecessor, Cardax Pharmaceuticals, Inc. (“Holdings”), was incorporated in the State of Delaware on March 23, 2006. Cardax, Inc. (the “Company”) (OTCQB:CDXI) is a biopharmaceutical company engaged in the development and commercialization of dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. The Company’s first commercial product, ZanthoSyn ® ® Going concern matters The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred net losses of $4,024,222 and $1,985,234 for the years ended December 31, 2018 and 2017, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $61,943,318 as of December 31, 2018, and has had negative cash flows from operating activities since inception. The Company expects that its marketing program for ZanthoSyn ® During the year ended December 31, 2018, the Company raised additional capital to carry out its business plan. As part of the Company’s efforts, it raised an additional $1.44 million in gross proceeds through the exchange of 9.6 million warrants via a warrant exchange offering that closed on July 27, 2018. Stock issuance costs associated with this capital raise totaled $196,006, for a net total $1,244,037 raised in this offering. The Company’s continued ability to raise additional capital through future equity and debt securities issuances is unknown. Obtaining additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Unaudited interim financial information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2019 and 2018. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 28, 2019. Revenue from contracts with customers In May 2014, the Financial Accounting Standards Board (“FASB”) issued a new standard related to revenue recognition. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted this standard effective January 1, 2018, using the retrospective method. As there was no impact on contracts that were previously completed and no significant impact to contracts completed after adoption, there was no need to restate prior results from operations. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended: September 30, 2019 September 30, 2018 Geographical area Source (Unaudited) (Unaudited) United States Nutraceuticals $ 439,505 $ 1,118,486 Hong Kong Nutraceuticals $ - $ 16,413 Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases The Company applied the modified retrospective approach in adopting this standard. The modified retrospective approach includes a number of optional practical expedients that the Company elected to apply; primarily the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. As part of this adoption, the Company will, in effect, continue to account for leases that commence before the effective date in accordance with previous U.S. GAAP unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous U.S. GAAP. This adoption of this standard on January 1, 2019, resulted in the Company recognizing a right-to-use asset and lease liability. The Company elected to not recognize any right-to-use assets or liabilities for leases that are twelve months or less. Lease costs are recognized straight-line over the term of the lease. The adoption of this standard did not impact retained earnings or cash flows of the Company. Derivative financial instruments The Company accounts for the fair value of the conversion feature in accordance with ASC 815-15, Derivatives and Hedging; Embedded Derivatives Other significant accounting policies There have been no other material changes to our significant accounting policies during the nine-months ended September 30, 2019, as compared to the significant accounting policies described in our Annual Report. Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation, such as reclassifying a separation agreement that has terms extending beyond one year. These reclassifications had no effect on the reported results of operations or cash flows.	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The consolidated financial statements have been consistently prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc., which was merged with and into Cardax, Inc. All significant intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and the accompanying notes. Estimates in these consolidated financial statements include asset valuations, estimates of future cash flows from and the economic useful lives of long-lived assets, valuations of stock compensation, certain accrued liabilities, income taxes and tax valuation allowances, and fair value estimates. Despite management’s intention to establish accurate estimates and reasonable assumptions, actual results could differ materially from these estimates and assumptions. Cash The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. The Company held no cash equivalents as of December 31, 2018 and 2017. The Company maintains cash deposit accounts at one financial institution. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company’s cash balance at times may exceed these limits. As of December 31, 2018 and 2017, the Company had $0 and $1,988,139, respectively, in excess of federally insured limits on deposit. Accounts receivable Accounts receivable of $157,082 and $37,243 as of December 31, 2018 and 2017, respectively, consists of amounts due from sales of dietary supplements. It is the Company’s policy to provide for an allowance for doubtful collections based upon a review of outstanding receivables, historical collection information, and existing economic conditions. Normal receivables are due 60 days after the issuance of the invoice. Receivables past due more than 90 days are considered delinquent. Delinquent receivables are written off based on individual credit evaluation and specific circumstances of the customer. There was no allowance necessary as of December 31, 2018 and 2017. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the average cost method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventory costs include third party costs for finished goods. The Company utilizes contract manufacturers and receives inventory in finished form. The Company provides a reserve against inventory for known or expected inventory obsolescence. The reserve is determined by specific review of inventory items for product age and quality that may affect salability. There were no reserves necessary for inventory as of December 31, 2018 and 2017. Property and equipment, net Property and equipment are recorded at cost, less depreciation. Equipment under capital lease obligations and leasehold improvements are amortized on the straight-line method over the shorter period of the lease term or the estimated useful life of the equipment. Such amortization is included in depreciation and amortization in the consolidated financial statements. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets are as follows. Furniture and office equipment 7 years Research and development equipment 3 to 7 years Information technology equipment 5 years Software 3 years Major additions and improvements are capitalized, and routine expenditures for repairs and maintenance are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is charged to income for the period. Impairment of long-lived assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets, as appropriate, may not be recoverable. When the sum of the undiscounted future net cash flows expected to result from the use and the eventual disposition is less than the carrying amounts, an impairment loss would be measured based on the discounted cash flows compared to the carrying amounts. There was no impairment charge recorded for the years ended December 31, 2018 and 2017. Revenue from contracts with customers In May 2014, the Financial Accounting Standards Board (“FASB”) issued a new standard related to revenue recognition. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted this standard effective January 1, 2018, using the retrospective method. As there was no impact on contracts that were previously completed and no significant impact to contracts completed after adoption, there was no need to restate prior results from operations. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the years ended December 31: Geographical area Source 2018 2017 United States Nutraceuticals $ 1,494,462 $ 610,323 Hong Kong Nutraceuticals $ 16,413 $ - Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. Sales discounts and other adjustments are recorded at the time of sale. Cost of goods sold Cost of goods sold is comprised of costs to manufacture or acquire products sold to customers, direct and indirect distribution costs, and other costs incurred in the sale of goods. Shipping and handling costs Shipping and handling costs are included in cost of goods sold. Shipping and handling costs were $21,603 and $10,366 for the years ended December 31, 2018 and 2017, respectively. Sales and use tax Revenues, as presented on the accompanying income statement, include taxes collected from customers and remitted to governmental authorities. Such taxes were $3,329 and $5,132 for the years ended December 31, 2018 and 2017, respectively. Research and development Research and development costs are expensed as incurred and consists primarily of manufacturing of products, third-party research, laboratory supplies, and scientific advisory boards. The focus of these costs is on the development of astaxanthin, zeaxanthin, and related compounds. For the years ended December 31, 2018 and 2017, research and development costs were $269,077 and $97,479, respectively. Advertising Advertising costs are expensed as incurred and are included as an element of sales and marketing costs in the accompanying consolidated statements of operations. For the years ended December 31, 2018 and 2017, advertising costs were $364,306 and $84,317, respectively. Income taxes The Company accounts for income taxes under an asset and liability approach. Deferred income taxes reflect the impact of temporary differences between assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax reporting purposes, net operating loss carry-forwards, and other tax credits measured by applying currently enacted tax laws. A valuation allowance is provided when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. The Company determines whether a tax position is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company uses a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company files income tax returns in the United States (“U.S.”) Federal and the States of Hawaii and California jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed. The Company did not recognize any tax liabilities for income taxes associated with unrecognized tax benefits as of December 31, 2018 and 2017. The Company’s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. In 2017, the Company adopted FASB issued Accounting Standards Update (“ASU”) No. 2015-17, Income Taxes (Topic 740) Fair value measurements U.S. GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; and ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. As of December 31, 2018 and 2017, there were no recurring fair value measurements of assets and liabilities subsequent to initial recognition. Stock based compensation The Company accounts for stock-based compensation costs under the provisions of FASB’s Accounting Standards Codification (“ASC”) No. 718, Compensation—Stock Compensation Equity Basic and diluted net loss per share Basic earnings per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding during the year. Diluted earnings per common share is calculated by dividing net loss for the year by the sum of the weighted average number of common shares outstanding during the year plus the number of potentially dilutive common shares (“dilutive securities”) that were outstanding during the year. Dilutive securities include options granted pursuant to the Company’s stock option plans, and warrants issued to non-employees. Potentially dilutive securities are excluded from the computation of earnings per share in periods in which a net loss is reported, as their effect would be antidilutive. Recently issued accounting pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement Fair Value Measurement The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements. Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Inventories

Inventories	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventories	NOTE 3 – INVENTORIES Inventories consist of the following as of: September 30, 2019 (Unaudited) December 31, 2018 Finished goods $ 533,139 $ 96,750 Raw materials 774,588 1,383,630 Total inventories $ 1,307,727 $ 1,480,380 As of September 30, 2019 and December 31, 2018, all raw materials were held at the manufacturer’s facility for future production.	NOTE 3 – INVENTORIES Inventories consist of the following as of December 31: 2018 2017 Finished goods $ 96,750 $ 240,917 Raw materials 1,383,630 98,937 Packing supplies and materials - 571 Total inventories $ 1,480,380 $ 340,425 As of December 31, 2018, $1,383,630 in raw materials were held at the manufacturer’s facility for future production.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	NOTE 4 – PROPERTY AND EQUIPMENT, net Property and equipment, net, consists of the following as of December 31: 2018 2017 Information technology equipment $ - $ 31,892 Less accumulated depreciation - (29,991 ) Total property and equipment, net $ - $ 1,901 Depreciation expense was $1,901 and $5,854 for the years ended December 31, 2018 and 2017, respectively. During the year ended December 31, 2018, the Company wrote off its fully depreciated equipment. There was no gain or loss recognized for this write-off.

Intangible Assets, Net

Intangible Assets, Net	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	NOTE 4 – INTANGIBLE ASSETS, net Intangible assets, net, consists of the following as of: September 30, 2019 (Unaudited) December 31, 2018 Patents $ 613,943 $ 578,326 Less accumulated amortization (321,614 ) (292,512 ) 292,329 285,814 Patents pending 135,292 148,720 Total intangible assets, net $ 427,621 $ 434,534 Patents are amortized straight-line over a period of fifteen years. Amortization expense was $10,074 and $29,102 for the three and nine-months ended September 30, 2019, respectively. Amortization expense was $6,717 and $21,952 for the three and nine-months ended September 30, 2018, respectively. The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved. During the three and nine-months ended September 30, 2019, the Company abandoned three patent applications in progress resulting in a loss of $36,205 on the abandonment of patents. The Company owns 29 issued patents, including 14 in the United States and 15 others in Europe, Canada, China, India, Japan, and Hong Kong. These patents will expire beginning in 2023 through 2028, subject to any patent term extensions of the individual patent. The Company has 2 patent applications pending in the United States and 2 foreign patent applications pending in Europe and the Patent Cooperation Treaty (“PCT”) countries.	NOTE 5 – INTANGIBLE ASSETS, net Intangible assets, net, consists of the following as of December 31: 2018 2017 Patents $ 578,326 $ 493,027 Less accumulated amortization (292,512 ) (263,843 ) 285,814 229,184 Patents pending 148,720 197,426 Total intangible assets, net $ 434,534 $ 426,610 Patents are amortized straight-line over a period of fifteen years. Amortization expense was $28,669 and $23,568 for the years ended December 31, 2018 and 2017, respectively. The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved. The Company owns 28 issued patents, including 14 in the United States and 14 others in Europe, Canada, China, India, Japan, and Hong Kong. These patents will expire beginning in 2023 through 2028, subject to any patent term extensions of the individual patent. The Company has 1 patent application pending in the United States and 2 patent applications pending in Europe and Brazil.

Accrued Separation Costs

Accrued Separation Costs	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued Separation Costs	NOTE 5 –ACCRUED SEPARATION COSTS On August 9, 2016, the Company entered into a separation agreement with an employee to pay $118,635 of accrued compensation over nine-years. As of September 30, 2019, $94,885 remains outstanding of which $9,000 is due within one-year and is reflected as a current liability.	NOTE 6 –ACCRUED SEPARATION COSTS On August 9, 2016, the Company entered into a separation agreement with an employee to pay $118,635 of accrued compensation over nine-years. This amount is included in accrued payroll and payroll related expenses in the accompanying consolidated balance sheets. This amount does not yield interest and matures as follows for the years ended December 31: 2019 $ 9,000 2020 9,000 2021 12,000 2022 12,000 2023 18,000 Thereafter 41,635 101,635 Less current portion (9,000 ) $ 92,635

Related Party Notes Payable

Related Party Notes Payable	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Notes Payable	NOTE 6 – RELATED PARTY NOTES PAYABLE Notes payable consisted of the following as of: September 30, 2019 December 31, 2018 (Unaudited) Inventory financing. $ 1,000,000 $ - Officer loan. 75,000 Promissory note. 500,000 - Total notes payable $ 1,575,000 $ - Less current portion (575,000 ) - Long term notes payable $ 1,000,000 $ - Interest expense The Company incurred interest charges of $45,925 and $101,385 during the three and nine-months ended September 30, 2019, respectively, on these notes payable of which $31,111 was accrued and payable as of September 30, 2019. Maturities Future maturities of notes payable are as follows as of September 30: 2020 $ 575,000 2021 - 2022 1,000,000 $ 1,575,000

Related Party Convertible Note

Related Party Convertible Note Payable	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Convertible Note Payable	NOTE 7 – RELATED PARTY CONVERTIBLE NOTE PAYABLE Related party convertible note payable consisted of the following as of: September 30, 2019 December 31, 2018 (Unaudited) Convertible note 2019-02. . $ 815,217 $ - Total notes payable 815,217 - Less original issue discounts (65,217 ) - Related party convertible note payable, net 750,000 - Less conversion rights and warrant discounts (286,050 ) - Plus amortization of discounts 73,898 - Total convertible notes payable, net $ 537,848 $ - Discounts Total discounts of $351,267 are amortized using the interest method, which resulted in amortization recorded as interest expense of $73,898 for the three and nine-months ended September 30, 2019. Interest expense The Company incurred interest charges of $13,222 during the three and nine-months ended September 30, 2019, on this related party convertible note payable of which $5,360 was accrued and payable as of September 30, 2019. Maturities Future maturities of notes payable are as follows as of September 30: 2020 $ 815,217 $ 815,217

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 8 – CONVERTIBLE NOTES PAYABLE Convertible notes payable consisted of the following as of: September 30, 2019 December 31, 2018 (Unaudited) Convertible note 2019-01. $ 150,000 $ - Convertible note 2019-03. 108,696 - September 30, 2019 December 31, 2018 (Unaudited) Convertible note 2019-04. 54,348 - Total notes payable 313,044 - Less original issue discounts (13,044 ) - Convertible notes payable, net 300,000 - Less conversion rights and warrant discounts (98,660 ) - Plus amortization of discounts 55,358 - Total convertible notes payable, net $ 256,698 $ - Discounts Total discounts of $111,704 are amortized using the interest method, which resulted in amortization recorded as interest expense of $31,696 and $55,358 for the three and nine-months ended September 30, 2019, respectively. Interest expense The Company incurred interest charges of $4,496 and $7,537 during the three and nine-months ended September 30, 2019, respectively, on these notes payable of which $7,537 was accrued and payable as of September 30, 2019. Maturities Future maturities of notes payable are as follows as of September 30: 2020 $ 313,044 $ 313,044

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	NOTE 9 – DERIVATIVE FINANCIAL INSTRUMENTS The Company has identified the embedded derivatives related to the convertible notes described in Note 8. These embedded derivatives included certain conversion and reset features. The accounting treatment of derivative financial instruments requires that the Company record fair value of these derivative liabilities as of the inception date of those convertible notes and each subsequent reporting date. The Company estimates the fair value of these derivative liabilities using the Black-Scholes valuation model. The initial value is used in the determination of a note discount with each subsequent change in fair value as a component of operations. The range of fair value assumptions used for derivative financial instruments during the nine-months ended September 30, 2019, were as follows: Dividend yield 0.0 % Risk-free rate 1.75% - 2.44 % Volatility 102% - 137 % Expected term 1 year Volatility was calculated based on the historical volatility of the Company. The risk-free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the derivative liabilities to be valued. The expected dividend yield was zero, because the Company does not anticipate paying a dividend within the relevant timeframe. For the nine-months ended September 30, 2019, the Company recognized total derivative liabilities and convertible note discounts of $243,275 based on the fair value at the convertible notes’ inception dates. These derivative liabilities were subsequently revalued at $246,414 as of September 30, 2019, which resulted in a loss of $3,139 on the change in value of these derivative liabilities. The following table presents the three-level hierarchy prescribed by U.S. GAAP for derivative liabilities since it is a liability that is measured and recognized at fair value on a recurring basis as of: Level 1 Level 2 Level 3 September 30, 2019 - - $ 246,414

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Equity [Abstract]
Stockholders' Deficit	NOTE 10 – STOCKHOLDERS’ DEFICIT Self-directed stock issuance 2019 During the nine-months ended September 30, 2019, the Company sold securities in a self-directed offering to existing stockholders of the Company in the aggregate amount of $245,000, respectively, at $0.30 per unit. Each $0.30 unit consisted of 2 shares of restricted common stock (1,633,330 shares) and a five-year warrant to purchase 1 share of restricted common stock (816,665 warrant shares) at $0.20 per share. Warrant exchange offering In June 2018, the Company commenced an offering to exchange outstanding warrants for shares of common stock under a Form S-4 Registration Statement. These shares of common stock were issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of common stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants and $1,440,043 in gross proceeds for 9,600,286 shares of common stock. Stock issuance costs associated with this capital raise totaled $196,006, resulting in a net total of $1,244,037 raised in this offering. Shares outstanding As of September 30, 2019 and December 31, 2018, the Company had a total of 137,261,594 and 133,888,573, respectively, shares of common stock outstanding.	NOTE 7 – STOCKHOLDERS’ DEFICIT Warrant exchange offering In June 2018, the Company commenced an offering to exchange outstanding warrants for shares of common stock under a Form S-4 Registration Statement. These shares of common stock were issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of common stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants and $1,440,043 in gross proceeds for 9,600,286 shares of common stock. Stock issuance costs associated with this capital raise totaled $196,006, resulting in a net total of $1,244,037 raised in this offering. Self-directed stock issuance During the year ended December 31, 2017, the Company sold securities in a self-directed offering in the aggregate amount of $179,000, $3,774,456, and $124,979 at $0.08, $0.12, and $0.30, respectively, per unit. Each $0.08 unit consisted of 1 share of restricted common stock (2,237,500 shares), a five-year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.08 per share, a five-year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.16 per share. Each $0.12 unit consisted of 1 share of restricted common stock (31,453,788 shares) and a five-year warrant to purchase 1 share of restricted common stock (31,453,788 warrant shares) at $0.12 per share. Each $0.30 unit consisted of 1 share of restricted common stock (416,595 shares) and a five-year warrant to purchase 1 share of restricted common stock (416,595 warrant shares) at $0.30 per share. Equity purchase agreement During the year ended December 31, 2017, the Company sold 567,644 shares of common stock for $60,000, pursuant to an equity purchase agreement. Payable settlement In May 2017, the Company settled a payable in the amount of $44,700 with a previously engaged broker dealer through the issuance of securities at $0.08 per unit. Each unit consisted of 1 share of restricted common stock (558,750 shares), a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.08 per share, a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.16 per share. Shares outstanding As of December 31, 2018 and 2017, the Company had a total of 133,888,573 and 122,674,516 shares of common stock outstanding.

Stock Grants

Stock Grants	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Equity [Abstract]
Stock Grants	NOTE 11 – STOCK GRANTS Director stock grants During the nine-months ended September 30, 2019 and 2018, the Company granted its independent directors an aggregate of 1,627,191 and 906,774, respectively, shares of restricted common stock in the Company. These shares were fully vested upon issuance. The increase in number of shares issued was due to the expansion of the Board of Directors by two members in September 2018. The expense recognized for these grants based on the grant date fair value was $262,500 and $200,000 for the nine-months ended September 30, 2019 and 2018, respectively. Consultant stock grants On April 10, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.23 per share. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on April 1, 2017. The Company recognized $0 and $5,750 in stock-based compensation related to this grant during the nine-months ended September 30, 2019 and 2018, respectively. On August 8, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.175 per share. These shares were subject to a risk of forfeiture and vested 25% upon grant and quarterly in arrears thereafter commencing on September 1, 2017. The Company recognized $0 and $4,375 in stock-based compensation related to this grant during the nine-months ended September 30, 2019 and 2018, respectively. On December 31, 2018, the Company granted consultants 112,500 shares of restricted common stock valued at $0.20 per share. These shares were fully vested upon issuance. The Company recognized $22,500 in stock-based compensation related to these grants during the year ended December 31, 2018. On March 31, 2019, the Company granted consultants 37,500 shares of restricted common stock valued at $0.17 per share. On June 30, 2019, the Company granted consultants 37,500 shares of restricted common stock valued at $0.125 per share. On September 30, 2019, the Company granted consultants 37,500 shares of restricted common stock valued at $0.089 per share. These shares were fully vested upon issuance. The Company recognized $14,400 in stock-based compensation related to these grants during the nine-months ended September 30, 2019.	NOTE 8 – STOCK GRANTS Director stock grants During 2018 and 2017, the Company granted its independent directors an aggregate of 1,344,274 and 793,025, respectively, shares of restricted common stock in the Company. These shares were fully vested upon issuance. The increase in number of shares issued was due to the expansion of the Board of Directors by two members in June 2018. The expense recognized for these grants based on the grant date fair value was $287,500 and $150,000 for the years ended December 31, 2018 and 2017, respectively. Consultant stock grants On April 10, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.23 per share. These shares are subject to a risk of forfeiture and vest quarterly in arrears commencing on April 1, 2017. The Company recognized $17,250 in stock-based compensation related to this grant during the year ended December 31, 2017. On August 8, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.175 per share. These shares are subject to a risk of forfeiture and vest 25% upon grant and quarterly in arrears thereafter commencing on September 1, 2017. The Company recognized $10,125 and $13,125 in stock-based compensation related to this grant during the years ended December 31, 2018 and 2017. On December 31, 2018, the Company granted consultants 112,500 shares of restricted common stock valued at $0.20 per share. These shares were fully vested upon issuance. The Company recognized $22,500 in stock-based compensation related to these grants during the year ended December 31, 2018.

Stock Option Plans

Stock Option Plans	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Stock Option Plans	NOTE 12 – STOCK OPTION PLANS On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares reserved under this plan upon adoption was 30,420,148. On April 16, 2015, the majority stockholder of the Company approved an increase in the Company’s 2014 Equity Compensation Plan by 15 million shares. On December 4, 2018, the stockholders of the Company approved an increase in the Company’s 2014 Equity Compensation Plan by an additional 5 million shares, for a total of 50,420,148 shares reserved under the plan. Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years. A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2018 38,213,427 $ 0.41 5.23 $ 562,456 Exercisable January 1, 2018 36,213,427 $ 0.41 4.98 $ 562,456 Canceled (350,000 ) Granted 2,833,334 Exercised (200,000 ) Forfeited - Outstanding December 31, 2018 40,496,761 $ 0.40 4.52 $ 986,808 Exercisable December 31, 2018 37,157,179 $ 0.41 4.10 $ 966,808 Canceled (58,336 ) Granted - Exercised - Forfeited - Outstanding September 30, 2019 40,438,425 $ 0.40 3.77 $ 149,089 Exercisable September 30, 2019 38,130,093 $ 0.41 3.48 $ 149,089 The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on September 30, 2019, based on a valuation of the Company’s stock for that day. A summary of the Company’s non-vested options for the nine-months ended September 30, 2019 and year ended December 31, 2018, are presented below: Non-vested at January 1, 2018 2,000,000 Granted 2,833,334 Vested (1,143,752 ) Canceled (350,000 ) Non-vested at December 31, 2018 3,339,582 Granted - Vested (972,914 ) Canceled (58,336 ) Non-vested at September 30, 2019 2,308,332 The Company estimates the fair value of stock options granted on each grant date using the Black-Scholes option valuation model and recognizes an expense ratably over the requisite service period. The range of fair value assumptions related to options issued were as follows for the: Nine-months ended Year ended Dividend yield 0.0 % 0.0 % Risk-free rate 2.38% - 3.04 % 2.38% - 3.04 % Volatility 214% - 226 % 214% - 226 % Expected term 3 - 7 years 3 - 7 years Volatility was calculated based on the historical volatility of the Company. The risk-free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected dividend yield was zero, because the Company does not anticipate paying a dividend within the relevant timeframe. The Company records forfeitures as they occur and reverses compensation cost previously recognized, in the period the award is forfeited, for an award that is forfeited before completion of the requisite service period. Stock option exercise During the year ended December 31, 2018, the Company issued 156,997 shares of common stock in connection with the cashless exercise of stock options for 100,000, 50,000, and 50,000 shares of common stock exercisable at $0.06 per share with 43,003 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price. Stock based compensation The Company recognized stock-based compensation expense related to options during the: Nine-months ended September 30 2019 2018 Amount Amount Service provider compensation $ 133,125 $ 76,250 Employee compensation 124,750 156,875 Total $ 257,875 $ 233,125	NOTE 9 – STOCK OPTION PLANS On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares that may be issued under this plan upon adoption was 30,420,148. On April 16, 2015, the majority stockholder of the Company approved an increase in the Company’s 2014 Equity Compensation Plan by 15 million shares, which was subsequently increased in December 2018 by an additional 5 million shares to allow for a total of 50,420,148 shares available under the plan. Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years. A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2017 36,821,969 $ 0.41 5.94 $ 301,273 Exercisable January 1, 2017 36,771,969 $ 0.41 5.94 $ 299,273 Canceled - Granted 2,161,458 Exercised (770,000 ) Forfeited - Outstanding December 31, 2017 38,213,427 $ 0.41 5.23 $ 562,456 Exercisable December 31, 2017 36,213,427 $ 0.41 4.98 $ 562,456 Canceled (350,000 ) Granted 2,833,334 Exercised (200,000 ) Forfeited - Outstanding December 31, 2018 40,496,761 $ 0.40 4.52 $ 986,808 Exercisable December 31, 2018 37,157,179 $ 0.41 4.10 $ 966,808 The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on December 31, 2018, based on a valuation of the Company’s stock for that day. A summary of the Company’s non-vested options for the years ended December 31, 2018 and 2017 are presented below: Non-vested at January 1, 2017 50,000 Granted 2,161,458 Vested (211,458 ) Canceled - Non-vested at December 31, 2017 2,000,000 Granted 2,833,334 Vested (1,143,752 ) Canceled (350,000 ) Non-vested at December 31, 2018 3,339,582 The Company estimates the fair value of stock options granted on each grant date using the Black-Scholes option valuation model and recognizes an expense ratably over the requisite service period. The range of fair value assumptions related to options issued were as follows for the years ended December 31: 2018 2017 Dividend yield 0.0 % 0.0 % Risk-free rate 2.38% - 3.04 % 1.89% - 2.26 % Expected volatility 214% - 226 % 221% - 232 % Expected term 3 - 7 years 5 - 7 years The expected volatility was calculated based on the historical volatility of the Company. The risk-free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected dividend yield was zero, because the Company does not anticipate paying a dividend within the relevant timeframe. Due to a lack of historical information needed to estimate the Company’s expected term, it was estimated using the simplified method allowed. The Company records forfeitures as they occur and reverses compensation cost previously recognized, in the period the award is forfeited, for an award that is forfeited before completion of the requisite service period. Stock option exercise During the year ended December 31, 2018, the Company issued 156,997 shares of common stock in connection with the cashless exercise of stock options for 100,000, 50,000, and 50,000 shares of common stock exercisable at $0.06 per share with 43,003 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price. During the year ended December 31, 2017, the Company issued 645,288 shares of common stock in connection with the cashless exercise of stock options for 100,000, 45,000, and 625,000 shares of common stock exercisable at $0.155, $0.06, and $0.06, respectively, per share with 124,712 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price. The Company recognized stock-based compensation expense related to options during the: Years ended December 31 2018 2017 Amount Amount Service provider compensation $ 124,896 $ 3,500 Employee compensation 205,250 33,271 Director compensation - 25,000 Total $ 330,146 $ 61,771

Warrants

Warrants	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Warrants	NOTE 13 – WARRANTS The following is a summary of the Company’s warrant activity: Warrants Weighted average exercise price Weighted average remaining contractual term in years Aggregate intrinsic value Outstanding January 1, 2018 127,434,122 $ 0.24 3.15 $ 3,957,689 Exercisable January 1, 2018 127,434,122 $ 0.24 3.15 $ 3,957,689 Canceled - Granted 315,010 Exercised (9,600,286 ) Expired (101,984 ) Outstanding December 31, 2018 118,046,862 $ 0.20 2.32 $ 7,848,637 Exercisable December 31, 2018 118,046,862 $ 0.20 2.32 $ 7,848,637 Canceled - Granted 3,116,665 Exercised - Expired (18,405,496 ) Outstanding September 30, 2019 102,758,031 $ 0.13 2.07 $ 146,779 Exercisable September 30, 2019 102,758,031 $ 0.13 2.07 $ 146,779 The Company estimates the fair value of warrants granted on each grant date using the Black-Scholes option valuation model. Volatility is calculated based on the historical volatility of the Company. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the warrants to be valued. The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. The Company did not recognize any stock-based compensation expense related to warrants during the three-months ended September 30, 2019 and 2018. Convertible note warrants Warrants to purchase 2,300,000 shares of common stock at $0.12 to $0.20 per share were issued in connection with the issuance of convertible notes. These warrants were immediately vested and expire in five years and were recorded as discounts on the convertible notes in the aggregate amount of $141,435. Warrant exchange offering In June 2018, the Company commenced an offering to exchange outstanding warrants for shares of common stock under a Form S-4 Registration Statement. These shares of common stock were issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of common stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants and $1,440,043 in gross proceeds for 9,600,286 shares of common stock. Stock issuance costs associated with this capital raise totaled $196,006, resulting in a net total of $1,244,037 raised in this offering. As part of this offering, warrants to purchase 315,010 shares of common stock at $0.21 per share were issued to investment bankers for their services. Warrant expiration During the nine-months ended September 30, 2019, warrants to purchase an aggregate of 18,405,496 shares of common stock expired. During the year ended December 31, 2018, warrants to purchase an aggregate of 101,984 shares of common stock expired.	NOTE 10 – WARRANTS The following is a summary of the Company’s warrant activity: Warrants Weighted Weighted Aggregate Outstanding January 1, 2017 88,365,036 $ 0.30 3.50 $ 543,770 Exercisable January 1, 2017 88,365,036 $ 0.30 3.50 $ 543,770 Canceled - Granted 40,259,133 Exercised (798,000 ) Forfeited (392,047 ) Outstanding December 31, 2017 127,434,122 $ 0.24 3.15 $ 3,957,689 Exercisable December 31, 2017 127,434,122 $ 0.24 3.15 $ 3,957,689 Canceled - Granted 315,010 Exercised (9,600,286 ) Forfeited (101,984 ) Outstanding December 31, 2018 118,046,862 $ 0.20 2.32 $ 7,848,637 Exercisable December 31, 2018 118,046,862 $ 0.20 2.32 $ 7,848,637 The Company estimates the fair value of warrants granted on each grant date using the Black-Scholes option valuation model. The expected volatility is calculated based on the historical volatility of the Company. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the warrants to be valued. The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. Due to a lack of historical information needed to estimate the Company’s expected term, it is estimated using the simplified method allowed. The Company did not recognize any stock-based compensation expense related to warrants during the years ended December 31, 2018 and 2017, respectively. Warrant exercise During the year ended December 31, 2017, the Company issued 233,217 shares of common stock in connection with the cashless exercise of a warrant for 298,000 shares of common stock at $0.10 per share with 64,783 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price. During the year ended December 31, 2017, the Company issued 500,000 shares of common stock in connection with the exercise of a warrant for 500,000 shares of common stock at $0.08 per share in exchange for $40,000. Warrant exchange offering In June 2018, the Company commenced an offering to exchange outstanding warrants for shares of common stock under a Form S-4 Registration Statement. These shares of common stock were issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of common stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants and $1,440,043 in gross proceeds for 9,600,286 shares of common stock. Stock issuance costs associated with this capital raise totaled $196,006, resulting in a net total of $1,244,037 raised in this offering. As part of this offering, warrants to purchase 315,010 shares of common stock at $0.21 per share were issued to investment bankers for their services. Warrant expiration During the years ended December 31, 2018 and 2017, warrants to purchase an aggregate of 101,984 and 392,047 shares of restricted common stock expired.

Income Taxes

Income Taxes	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 14 – INCOME TAXES The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed. The effective tax rate for the three and three-months ended September 30, 2019 and 2018, differs from the statutory rate of 21% as a result of state taxes (net of Federal benefit), permanent differences, and a reserve against deferred tax assets. The Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes Recent tax legislation On March 22, 2018, the Tax Cuts and Jobs Act (“TCJA”) was enacted into law, which significantly changes existing U.S. tax law and includes numerous provisions that affect our business, such as reducing the U.S. federal statutory tax rate from 35% to 21% effective January 1, 2018. Uncertain tax positions The Company is subject to taxation in the United States and three state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events. Uncertain tax positions (continued) As of September 30, 2019 and December 31, 2018, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its condensed consolidated statements of operations, which is consistent with the recognition of these items in prior reporting periods. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed.	NOTE 11 – INCOME TAXES The following table presents a reconciliation of the statutory Federal rate and the Company’s effective tax rate for the years ended December 31: 2018 2017 Tax provision (benefit) at Federal statutory rate (21.00 )% (34.00 )% Accrued compensation (0.28 )% (0.32 )% Stock based compensation 3.37 % 4.15 % Depreciation and amortization 0.15 % 0.59 % Other 0.07 % 0.26 % Change in valuation allowance 17.69 % 29.32 % Effective tax rate 0.00 % 0.00 % The effective tax rate for the three and years ended December 31, 2018 and 2017, differs from the statutory rate of 21% and 34% for the years ended December 31, 2018 and 2017, respectively, as a result of state taxes (net of Federal benefit), permanent differences, and a reserve against deferred tax assets. There was not a provision for income taxes for the years ended December 31, 2018 and 2017. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company’s deferred tax assets and liabilities for the years ended December 31: 2018 2017 DEFERRED TAX ASSETS, net: Net operating loss carryforwards $ 9,633,893 $ 8,705,467 Accrued compensation 1,080,432 1,074,903 Stock based compensation 178,174 66,348 Credit carryforwards 52,592 71,910 Depreciation and amortization carryforwards (63,917 ) (71,054 ) Total 10,881,174 9,847,574 Less valuation allowance (10,881,174 ) (9,847,574 ) NET DEFERRED TAX ASSETS $ - $ - As of December 31, 2018, the Company had a Federal net operating loss carryforward of $36,950,157. In addition, the Company had a net operating loss carryforward for Hawaii income tax purposes of $29,286,880 as of December 31, 2018. These amounts may be used to offset up to 80% of future taxable income and differ from the Company’s accumulated deficit due to permanent and temporary tax differences. The Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes Recent tax legislation On December 22, 2017, the Tax Cuts and Jobs Act (“TCJA”) was enacted into law, which significantly changes existing U.S. tax law and includes numerous provisions that affect our business, such as reducing the U.S. federal statutory tax rate. The TCJA reduces the U.S. federal statutory tax rate from 35% to 21% effective January 1, 2018. As a result of TCJA, the Company recorded a change in its deferred tax asset of approximately, $3.8 million for the year ended December 31, 2017, which was offset by an adjustment to the allowance. State tax credits The Company received a refundable tax credit of $17,253 from the State of Hawaii during the year ended December 31, 2017. This amount is recorded as other income in the consolidated statement of operations.

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	NOTE 15 – BASIC AND DILUTED NET LOSS PER SHARE The following table sets forth the computation of the Company’s basic and diluted net loss per share for: Three-months ended September 30, 2019 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,433,626 ) 136,640,761 $ (0.01 ) Effect of dilutive securities—Common stock options, warrants, and convertible note - - - Diluted loss per share $ (1,433,626 ) 136,640,761 $ (0.01 ) Three-months ended September 30, 2018 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (928,888 ) 130,083,598 $ (0.01 ) Effect of dilutive securities—Common stock options, warrants, and convertible note - - - Diluted loss per share $ (928,888 ) 130,083,598 $ (0.01 ) Nine-months ended September 30, 2019 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (3,650,740 ) 135,516,490 (0.03 ) Effect of dilutive securities—Common stock options, warrants, and convertible note - - - Diluted loss per share $ (3,650,740 ) 135,516,490 (0.03 ) Nine-months ended September 30, 2018 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (3,076,873 ) 125,271,516 $ (0.02 ) Effect of dilutive securities—Common stock options, warrants, and convertible note - - - Diluted loss per share $ 3,076,873 125,271,516 $ (0.02 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended: September 30, 2019 September 30, 2018 (Unaudited) (Unaudited) Convertible notes 9,490,186 - Common stock options 40,438,425 39,496,761 Common stock warrants 102,758,031 118,148,846 Total common stock equivalents 152,686,642 157,645,607	NOTE 12 – BASIC AND DILUTED NET LOSS PER SHARE The following table sets forth the computation of the Company’s basic and diluted net loss per share for the years ended December 31: 2018 Net Loss Shares Per share Basic loss per share $ (4,024,222 ) 127,304,856 $ (0.03 ) Effect of dilutive securities—Common stock options and warrants - - - Diluted loss per share $ (4,024,222 ) 127,304,856 $ (0.03 ) 2017 Net Loss Shares Per share Basic loss per share $ (1,985,234 ) 99,951,385 $ (0.02 ) Effect of dilutive securities—Common stock options and warrants - - - Diluted loss per share $ (1,985,234 ) 99,951,385 $ (0.02 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the years ended December 31: 2018 2017 Common stock options 40,496,761 38,213,427 Common stock warrants 118,046,862 127,434,122 Total common stock equivalents 158,543,623 165,647,549

Leases

Leases	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Leases [Abstract]
Leases	NOTE 16 – LEASES Manoa Innovation Center The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $8,989 and $27,188 for the three and nine-months ended September 30, 2019, respectively, and $8,760 and $29,662 for the three and nine-months ended September 30, 2018, respectively. Fleet Lease In January 2018, the Company entered into a vehicle lease arrangement with a rental company for three vehicles. The terms of the leases require monthly payments of $1,619 for three years. These leases convert to month-to-month leases in January 2021 unless terminated. Total lease expense under this agreement was $4,964 and $16,520 for the three and nine-months ended September 30, 2019, respectively, and $5,602 and $14,953 for the three and nine-months ended September 30, 2018, respectively. Right-to-use leased asset and liability As a result of the adoption of ASU No. 2016-02, Leases	NOTE 13 – LEASES Manoa Innovation Center The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $39,302 and $29,690, for the years ended December 31, 2018 and 2017, respectively. Fleet Lease In January 2018, the Company entered into a vehicle lease arrangement with a rental company for three vehicles. The terms of the leases require monthly payments of $1,619 for three years. These leases convert to month-to-month leases in January 2021 unless terminated. Total lease expense under this agreement was $21,196 for the year ended December 31, 2018. Future minimum lease payments are as follows for the years ended December 31: 2019 $ 17,868 2020 17,868 2021 1,489 $ 37,225

Commitments

Commitments	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 14 – COMMITMENTS Patent payable As part of the formation of the Company, a patent license was transferred to the Company. The original license began in 2006. Under the terms of the license the Company agreed to pay $10,000 per year through 2015 and royalties of 2% on any revenues resulting from the license. There were no revenues generated by this license during the years ended December 31, 2018 and 2017. The remaining obligation of $20,000 as of December 31, 2018 and 2017, is recorded as a part of accounts payable on the consolidated balance sheets. The license expired in February 2016. Employee settlement As of December 31, 2018 and 2017, the Company owed a former employee a severance settlement payable in the amount of $50,000 for accrued vacation benefits. As part of the severance settlement, a stock option previously granted to the former employee was fully vested and extended. BASF agreement and license In November 2006, the Company entered into a joint development and supply agreement with BASF SE (“BASF”). Under the agreement, the Company granted BASF an exclusive world-wide license to the Company’s rights related to the development and commercialization of astaxanthin nutraceutical products; the Company retains all rights related to astaxanthin pharmaceutical products. The Company is to receive specified royalties based on future net sales of such astaxanthin nutraceutical products. No royalties were realized from this agreement during the years ended December 31, 2018 and 2017. Capsugel agreement On August 18, 2014, the Company entered into a collaboration agreement with Capsugel US, LLC (“Capsugel”) for the joint commercial development of astaxanthin products (“Capsugel Astaxanthin Products”) for the consumer health market that contain nature-identical synthetic astaxanthin and use Capsugel’s proprietary formulation technology. The agreement provides for the parties to jointly administer activities under a product development plan that will include identifying at least one mutually acceptable third-party marketer who will further develop, market and distribute Capsugel Astaxanthin Products. Capsugel will share revenues with the Company based on net sales of products that are developed under the collaboration. No revenues were realized from this agreement during the years ended December 31, 2018 and 2017.

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 17 – SUBSEQUENT EVENTS The Company evaluated all material events through the date the financials were ready for issuance and identified the following for additional disclosure. Convertible Notes On the dates set forth in the table below , the Company entered into convertible notes with lenders, who are also current stockholders, for the amounts set forth in the table below. Each of these notes accrues interest payable monthly at the rate of 8% per annum and matures on June 30, 2020. Each of these notes and accrued interest thereon may convert into shares of common stock at the conversion price set forth in the table below any time at the holder’s option. If any of these notes, or any portion thereof, has not been repaid or converted in full on or prior to the maturity date, then repayment of the unpaid principal balance plus any accrued and unpaid interest thereon, shall be amortized over the following thirty-six (36) months. The Company has the right to prepay each of these notes without penalty or premium. Each of these notes were issued with detachable five-year warrants to purchase shares of common stock as set forth in the table below. Issuance Date Principal Amount Original Issue Discount Gross Proceeds Note Conversion Price Per Share Number of Shares Underlying Warrants Warrant Exercise Price Per Share October 3, 2019 $ 27,174 $ 2,174 $ 25,000 $ 0.12 50,000 $ 0.12 October 10, 2019 27,174 2,174 25,000 0.12 50,000 0.12 October 23, 2019 108,696 8,696 100,000 0.12 250,000 250,000 0.15 0.20 October 29, 2019 27,174 2,174 25,000 0.12 50,000 0.12 November 8, 2019 16,304 1,304 15,000 0.07 30,000 0.07 Total $ 206,522 $ 16,522 $ 190,000 $ 0.07-0.12 680,000 $ 0.07-0.20 On the date set forth in the table below, the Company entered into a senior convertible note payable with a lender, who is also a current stockholder and beneficial owner of more than 5% of the Company’s common stock, in the amount set forth in the table below. This note accrues interest payable monthly at the rate of 8% per annum and matures on June 30, 2020. This note and accrued interest thereon may convert into shares of common stock at the conversion price then in effect (initially $0.12 per share, subject to adjustment) any time at the holder’s option or automatically upon a qualified financing of at least $5 million at the lower of the conversion price then in effect or a 25% discount to the offering price. The conversion price is subject to adjustment upon the issuance of the Company’s common stock or securities convertible into common stock at a price per share less than the then prevailing conversion price, other than specified exempt issuances; accordingly, on November 8, 2019, the conversion price was adjusted to $0.07 per share. The Company has the right to prepay this note without penalty or premium. This note was issued with a detachable five-year warrant to purchase shares of common stock as set forth in the table below. The exercise price of this warrant shall be adjusted in accordance with any adjustment to the conversion price of this note; accordingly, on November 8, 2019, the exercise price was adjusted to $0.07 per share. Issuance Date Principal Amount Original Issue Discount Gross Proceeds Note Conversion Price Per Share Number of Shares Underlying Warrants Warrant Exercise Price Per Share October 16, 2019 $ 217,391 $ 17,391 $ 200,000 $ 0.07 400,000 $ 0.07 General Nutrition Corporation On October 16, 2019, the exclusivity provision of the Company’s purchasing agreement with GNC expired, however, all other provisions of the Company’s purchasing agreement with GNC remain in effect. The Company may expand ZanthoSyn® distribution to mass market retailers, other specialty nutrition stores, pharmacies, and other retailers. The Company also plans to increase its sales and marketing efforts through e-commerce.	NOTE 15 – SUBSEQUENT EVENTS The Company evaluated all material events through the date the financials were ready for issuance and noted the following non-recognized events for disclosure. On January 11, 2019, the Company entered into a $1,000,000 revolving inventory financing facility with a lender. Use of proceeds from this facility is limited to the purchase of inventory, including raw materials, intermediates, and finished goods, unless otherwise waived by the lender. This facility accrues interest at the rate of 12% per annum, is unsecured, and matures in three years from origination. This facility also requires monthly interest payments. As of March 27, 2019, the aggregate unpaid principal amount under this facility was $1,000,000. On February 7, 2019, the Company registered 167,730,236 shares of its common stock, par value $0.001 per share, held by the registering stockholders, consisting of (i) 69,115,849 shares of its issued and outstanding common stock, and (ii) 98,614,387 shares of its common stock that may be issued upon the exercise of outstanding warrants. On February 22, 2019, the Company sold securities in a self-directed offering in the aggregate amount of $20,000 at $0.30 per unit. Each unit consisted of 2 shares of restricted common stock (133,332 shares) and a five-year warrant to purchase 1 share of restricted common stock (66,666 warrant shares) at $0.20 per share.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation		Basis of presentation The consolidated financial statements have been consistently prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc., which was merged with and into Cardax, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates		Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and the accompanying notes. Estimates in these consolidated financial statements include asset valuations, estimates of future cash flows from and the economic useful lives of long-lived assets, valuations of stock compensation, certain accrued liabilities, income taxes and tax valuation allowances, and fair value estimates. Despite management’s intention to establish accurate estimates and reasonable assumptions, actual results could differ materially from these estimates and assumptions.
Cash		Cash The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. The Company held no cash equivalents as of December 31, 2018 and 2017. The Company maintains cash deposit accounts at one financial institution. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company’s cash balance at times may exceed these limits. As of December 31, 2018 and 2017, the Company had $0 and $1,988,139, respectively, in excess of federally insured limits on deposit.
Accounts Receivable		Accounts receivable Accounts receivable of $157,082 and $37,243 as of December 31, 2018 and 2017, respectively, consists of amounts due from sales of dietary supplements. It is the Company’s policy to provide for an allowance for doubtful collections based upon a review of outstanding receivables, historical collection information, and existing economic conditions. Normal receivables are due 60 days after the issuance of the invoice. Receivables past due more than 90 days are considered delinquent. Delinquent receivables are written off based on individual credit evaluation and specific circumstances of the customer. There was no allowance necessary as of December 31, 2018 and 2017.
Inventories		Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the average cost method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventory costs include third party costs for finished goods. The Company utilizes contract manufacturers and receives inventory in finished form. The Company provides a reserve against inventory for known or expected inventory obsolescence. The reserve is determined by specific review of inventory items for product age and quality that may affect salability. There were no reserves necessary for inventory as of December 31, 2018 and 2017.
Property and Equipment, Net		Property and equipment, net Property and equipment are recorded at cost, less depreciation. Equipment under capital lease obligations and leasehold improvements are amortized on the straight-line method over the shorter period of the lease term or the estimated useful life of the equipment. Such amortization is included in depreciation and amortization in the consolidated financial statements. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets are as follows. Furniture and office equipment 7 years Research and development equipment 3 to 7 years Information technology equipment 5 years Software 3 years Major additions and improvements are capitalized, and routine expenditures for repairs and maintenance are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is charged to income for the period.
Impairment of Long-lived Assets		Impairment of long-lived assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets, as appropriate, may not be recoverable. When the sum of the undiscounted future net cash flows expected to result from the use and the eventual disposition is less than the carrying amounts, an impairment loss would be measured based on the discounted cash flows compared to the carrying amounts. There was no impairment charge recorded for the years ended December 31, 2018 and 2017.
Unaudited Interim Financial Information	Unaudited interim financial information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2019 and 2018. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 28, 2019.
Revenue from Contracts with Customers	Revenue from contracts with customers In May 2014, the Financial Accounting Standards Board (“FASB”) issued a new standard related to revenue recognition. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted this standard effective January 1, 2018, using the retrospective method. As there was no impact on contracts that were previously completed and no significant impact to contracts completed after adoption, there was no need to restate prior results from operations. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended: September 30, 2019 September 30, 2018 Geographical area Source (Unaudited) (Unaudited) United States Nutraceuticals $ 439,505 $ 1,118,486 Hong Kong Nutraceuticals $ - $ 16,413 Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale.	Revenue from contracts with customers In May 2014, the Financial Accounting Standards Board (“FASB”) issued a new standard related to revenue recognition. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted this standard effective January 1, 2018, using the retrospective method. As there was no impact on contracts that were previously completed and no significant impact to contracts completed after adoption, there was no need to restate prior results from operations. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the years ended December 31: Geographical area Source 2018 2017 United States Nutraceuticals $ 1,494,462 $ 610,323 Hong Kong Nutraceuticals $ 16,413 $ - Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. Sales discounts and other adjustments are recorded at the time of sale.
Cost of Goods Sold		Cost of goods sold Cost of goods sold is comprised of costs to manufacture or acquire products sold to customers, direct and indirect distribution costs, and other costs incurred in the sale of goods.
Shipping and Handling Costs		Shipping and handling costs Shipping and handling costs are included in cost of goods sold. Shipping and handling costs were $21,603 and $10,366 for the years ended December 31, 2018 and 2017, respectively.
Sales and Use Tax		Sales and use tax Revenues, as presented on the accompanying income statement, include taxes collected from customers and remitted to governmental authorities. Such taxes were $3,329 and $5,132 for the years ended December 31, 2018 and 2017, respectively.
Research and Development		Research and development Research and development costs are expensed as incurred and consists primarily of manufacturing of products, third-party research, laboratory supplies, and scientific advisory boards. The focus of these costs is on the development of astaxanthin, zeaxanthin, and related compounds. For the years ended December 31, 2018 and 2017, research and development costs were $269,077 and $97,479, respectively.
Advertising		Advertising Advertising costs are expensed as incurred and are included as an element of sales and marketing costs in the accompanying consolidated statements of operations. For the years ended December 31, 2018 and 2017, advertising costs were $364,306 and $84,317, respectively.
Income Taxes		Income taxes The Company accounts for income taxes under an asset and liability approach. Deferred income taxes reflect the impact of temporary differences between assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax reporting purposes, net operating loss carry-forwards, and other tax credits measured by applying currently enacted tax laws. A valuation allowance is provided when necessary to reduce deferred tax assets to an amount that is more likely than not to be realized. The Company determines whether a tax position is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company uses a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company files income tax returns in the United States (“U.S.”) Federal and the States of Hawaii and California jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed. The Company did not recognize any tax liabilities for income taxes associated with unrecognized tax benefits as of December 31, 2018 and 2017. The Company’s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. In 2017, the Company adopted FASB issued Accounting Standards Update (“ASU”) No. 2015-17, Income Taxes (Topic 740)
Fair Value Measurements		Fair value measurements U.S. GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; and ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. As of December 31, 2018 and 2017, there were no recurring fair value measurements of assets and liabilities subsequent to initial recognition.
Stock Based Compensation		Stock based compensation The Company accounts for stock-based compensation costs under the provisions of FASB’s Accounting Standards Codification (“ASC”) No. 718, Compensation—Stock Compensation Equity
Basic and Diluted Net Loss Per Share		Basic and diluted net loss per share Basic earnings per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding during the year. Diluted earnings per common share is calculated by dividing net loss for the year by the sum of the weighted average number of common shares outstanding during the year plus the number of potentially dilutive common shares (“dilutive securities”) that were outstanding during the year. Dilutive securities include options granted pursuant to the Company’s stock option plans, and warrants issued to non-employees. Potentially dilutive securities are excluded from the computation of earnings per share in periods in which a net loss is reported, as their effect would be antidilutive.
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases The Company applied the modified retrospective approach in adopting this standard. The modified retrospective approach includes a number of optional practical expedients that the Company elected to apply; primarily the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. As part of this adoption, the Company will, in effect, continue to account for leases that commence before the effective date in accordance with previous U.S. GAAP unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous U.S. GAAP. This adoption of this standard on January 1, 2019, resulted in the Company recognizing a right-to-use asset and lease liability. The Company elected to not recognize any right-to-use assets or liabilities for leases that are twelve months or less. Lease costs are recognized straight-line over the term of the lease. The adoption of this standard did not impact retained earnings or cash flows of the Company.
Derivative Financial Instruments	Derivative financial instruments The Company accounts for the fair value of the conversion feature in accordance with ASC 815-15, Derivatives and Hedging; Embedded Derivatives
Other Significant Accounting Policies	Other significant accounting policies There have been no other material changes to our significant accounting policies during the nine-months ended September 30, 2019, as compared to the significant accounting policies described in our Annual Report.
Recently Issued Accounting Pronouncements		Recently issued accounting pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement Fair Value Measurement The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements.
Reclassifications	Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation, such as reclassifying a separation agreement that has terms extending beyond one year. These reclassifications had no effect on the reported results of operations or cash flows.	Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Depreciation of Estimated Useful Lives		Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets are as follows. Furniture and office equipment 7 years Research and development equipment 3 to 7 years Information technology equipment 5 years Software 3 years
Schedule of Revenues Disaggregated by Revenue Source and Geographical Location	The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended: September 30, 2019 September 30, 2018 Geographical area Source (Unaudited) (Unaudited) United States Nutraceuticals $ 439,505 $ 1,118,486 Hong Kong Nutraceuticals $ - $ 16,413	The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the years ended December 31: Geographical area Source 2018 2017 United States Nutraceuticals $ 1,494,462 $ 610,323 Hong Kong Nutraceuticals $ 16,413 $ -

Inventories (Tables)

Inventories (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following as of: September 30, 2019 (Unaudited) December 31, 2018 Finished goods $ 533,139 $ 96,750 Raw materials 774,588 1,383,630 Total inventories $ 1,307,727 $ 1,480,380	Inventories consist of the following as of December 31: 2018 2017 Finished goods $ 96,750 $ 240,917 Raw materials 1,383,630 98,937 Packing supplies and materials - 571 Total inventories $ 1,480,380 $ 340,425

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net, consists of the following as of December 31: 2018 2017 Information technology equipment $ - $ 31,892 Less accumulated depreciation - (29,991 ) Total property and equipment, net $ - $ 1,901

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Net	Intangible assets, net, consists of the following as of: September 30, 2019 (Unaudited) December 31, 2018 Patents $ 613,943 $ 578,326 Less accumulated amortization (321,614 ) (292,512 ) 292,329 285,814 Patents pending 135,292 148,720 Total intangible assets, net $ 427,621 $ 434,534	Intangible assets, net, consists of the following as of December 31: 2018 2017 Patents $ 578,326 $ 493,027 Less accumulated amortization (292,512 ) (263,843 ) 285,814 229,184 Patents pending 148,720 197,426 Total intangible assets, net $ 434,534 $ 426,610

Accrued Separation Costs (Table

Accrued Separation Costs (Tables)	12 Months Ended
	Dec. 31, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Payroll and Payroll Related Expenses	This amount does not yield interest and matures as follows for the years ended December 31: 2019 $ 9,000 2020 9,000 2021 12,000 2022 12,000 2023 18,000 Thereafter 41,635 101,635 Less current portion (9,000 ) $ 92,635

Related Party Notes Payable (Ta

Related Party Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Schedule of Related Party Notes Payable	Notes payable consisted of the following as of: September 30, 2019 December 31, 2018 (Unaudited) Inventory financing. $ 1,000,000 $ - Officer loan. 75,000 Promissory note. 500,000 - Total notes payable $ 1,575,000 $ - Less current portion (575,000 ) - Long term notes payable $ 1,000,000 $ -
Schedule of Related Party Future Maturities of Notes Payable	Future maturities of notes payable are as follows as of September 30: 2020 $ 575,000 2021 - 2022 1,000,000 $ 1,575,000

Related Party Convertible Not_2

Related Party Convertible Note Payable (Tables)	9 Months Ended
	Sep. 30, 2019
Related Party Transactions [Abstract]
Schedule of Related Party Convertible Note Payable	Related party convertible note payable consisted of the following as of: September 30, 2019 December 31, 2018 (Unaudited) Convertible note 2019-02. . $ 815,217 $ - Total notes payable 815,217 - Less original issue discounts (65,217 ) - Related party convertible note payable, net 750,000 - Less conversion rights and warrant discounts (286,050 ) - Plus amortization of discounts 73,898 - Total convertible notes payable, net $ 537,848 $ -
Schedule of Related Party Future Maturities of Convertible Notes Payable	Future maturities of notes payable are as follows as of September 30: 2020 $ 815,217 $ 815,217

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consisted of the following as of: September 30, 2019 December 31, 2018 (Unaudited) Convertible note 2019-01. $ 150,000 $ - Convertible note 2019-03. 108,696 - September 30, 2019 December 31, 2018 (Unaudited) Convertible note 2019-04. 54,348 - Total notes payable 313,044 - Less original issue discounts (13,044 ) - Convertible notes payable, net 300,000 - Less conversion rights and warrant discounts (98,660 ) - Plus amortization of discounts 55,358 - Total convertible notes payable, net $ 256,698 $ -
Schedule of Future Maturities of Convertible Notes Payable	Future maturities of notes payable are as follows as of September 30: 2020 $ 313,044 $ 313,044

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value Assumptions Related to Option Issued	The Company estimates the fair value of these derivative liabilities using the Black-Scholes valuation model. The initial value is used in the determination of a note discount with each subsequent change in fair value as a component of operations. The range of fair value assumptions used for derivative financial instruments during the nine-months ended September 30, 2019, were as follows: Dividend yield 0.0 % Risk-free rate 1.75% - 2.44 % Volatility 102% - 137 % Expected term 1 year The following table presents the three-level hierarchy prescribed by U.S. GAAP for derivative liabilities since it is a liability that is measured and recognized at fair value on a recurring basis as of: Level 1 Level 2 Level 3 September 30, 2019 - - $ 246,414

Stock Option Plans (Tables)

Stock Option Plans (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2018 38,213,427 $ 0.41 5.23 $ 562,456 Exercisable January 1, 2018 36,213,427 $ 0.41 4.98 $ 562,456 Canceled (350,000 ) Granted 2,833,334 Exercised (200,000 ) Forfeited - Outstanding December 31, 2018 40,496,761 $ 0.40 4.52 $ 986,808 Exercisable December 31, 2018 37,157,179 $ 0.41 4.10 $ 966,808 Canceled (58,336 ) Granted - Exercised - Forfeited - Outstanding September 30, 2019 40,438,425 $ 0.40 3.77 $ 149,089 Exercisable September 30, 2019 38,130,093 $ 0.41 3.48 $ 149,089	A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2017 36,821,969 $ 0.41 5.94 $ 301,273 Exercisable January 1, 2017 36,771,969 $ 0.41 5.94 $ 299,273 Canceled - Granted 2,161,458 Exercised (770,000 ) Forfeited - Outstanding December 31, 2017 38,213,427 $ 0.41 5.23 $ 562,456 Exercisable December 31, 2017 36,213,427 $ 0.41 4.98 $ 562,456 Canceled (350,000 ) Granted 2,833,334 Exercised (200,000 ) Forfeited - Outstanding December 31, 2018 40,496,761 $ 0.40 4.52 $ 986,808 Exercisable December 31, 2018 37,157,179 $ 0.41 4.10 $ 966,808
Schedule of Non-vested Shares Granted Under Stock Option Plan	A summary of the Company’s non-vested options for the nine-months ended September 30, 2019 and year ended December 31, 2018, are presented below: Non-vested at January 1, 2018 2,000,000 Granted 2,833,334 Vested (1,143,752 ) Canceled (350,000 ) Non-vested at December 31, 2018 3,339,582 Granted - Vested (972,914 ) Canceled (58,336 ) Non-vested at September 30, 2019 2,308,332	A summary of the Company’s non-vested options for the years ended December 31, 2018 and 2017 are presented below: Non-vested at January 1, 2017 50,000 Granted 2,161,458 Vested (211,458 ) Canceled - Non-vested at December 31, 2017 2,000,000 Granted 2,833,334 Vested (1,143,752 ) Canceled (350,000 ) Non-vested at December 31, 2018 3,339,582
Schedule of Fair Value Assumptions	The range of fair value assumptions related to options issued were as follows for the: Nine-months ended Year ended Dividend yield 0.0 % 0.0 % Risk-free rate 2.38% - 3.04 % 2.38% - 3.04 % Volatility 214% - 226 % 214% - 226 % Expected term 3 - 7 years 3 - 7 years	The range of fair value assumptions related to options issued were as follows for the years ended December 31: 2018 2017 Dividend yield 0.0 % 0.0 % Risk-free rate 2.38% - 3.04 % 1.89% - 2.26 % Expected volatility 214% - 226 % 221% - 232 % Expected term 3 - 7 years 5 - 7 years
Schedule of Recognized Stock Based Compensation Expense	The Company recognized stock-based compensation expense related to options during the: Nine-months ended September 30 2019 2018 Amount Amount Service provider compensation $ 133,125 $ 76,250 Employee compensation 124,750 156,875 Total $ 257,875 $ 233,125	The Company recognized stock-based compensation expense related to options during the: Years ended December 31 2018 2017 Amount Amount Service provider compensation $ 124,896 $ 3,500 Employee compensation 205,250 33,271 Director compensation - 25,000 Total $ 330,146 $ 61,771

Warrants (Tables)

Warrants (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Schedule of Stock Warrants Activity	The following is a summary of the Company’s warrant activity: Warrants Weighted average exercise price Weighted average remaining contractual term in years Aggregate intrinsic value Outstanding January 1, 2018 127,434,122 $ 0.24 3.15 $ 3,957,689 Exercisable January 1, 2018 127,434,122 $ 0.24 3.15 $ 3,957,689 Canceled - Granted 315,010 Exercised (9,600,286 ) Expired (101,984 ) Outstanding December 31, 2018 118,046,862 $ 0.20 2.32 $ 7,848,637 Exercisable December 31, 2018 118,046,862 $ 0.20 2.32 $ 7,848,637 Canceled - Granted 3,116,665 Exercised - Expired (18,405,496 ) Outstanding September 30, 2019 102,758,031 $ 0.13 2.07 $ 146,779 Exercisable September 30, 2019 102,758,031 $ 0.13 2.07 $ 146,779	The following is a summary of the Company’s warrant activity: Warrants Weighted Weighted Aggregate Outstanding January 1, 2017 88,365,036 $ 0.30 3.50 $ 543,770 Exercisable January 1, 2017 88,365,036 $ 0.30 3.50 $ 543,770 Canceled - Granted 40,259,133 Exercised (798,000 ) Forfeited (392,047 ) Outstanding December 31, 2017 127,434,122 $ 0.24 3.15 $ 3,957,689 Exercisable December 31, 2017 127,434,122 $ 0.24 3.15 $ 3,957,689 Canceled - Granted 315,010 Exercised (9,600,286 ) Forfeited (101,984 ) Outstanding December 31, 2018 118,046,862 $ 0.20 2.32 $ 7,848,637 Exercisable December 31, 2018 118,046,862 $ 0.20 2.32 $ 7,848,637

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Effective Income Taxes Rate	The following table presents a reconciliation of the statutory Federal rate and the Company’s effective tax rate for the years ended December 31: 2018 2017 Tax provision (benefit) at Federal statutory rate (21.00 )% (34.00 )% Accrued compensation (0.28 )% (0.32 )% Stock based compensation 3.37 % 4.15 % Depreciation and amortization 0.15 % 0.59 % Other 0.07 % 0.26 % Change in valuation allowance 17.69 % 29.32 % Effective tax rate 0.00 % 0.00 %
Schedule of Deferred Income Tax Assets and Liabilities	The following table presents significant components of the Company’s deferred tax assets and liabilities for the years ended December 31: 2018 2017 DEFERRED TAX ASSETS, net: Net operating loss carryforwards $ 9,633,893 $ 8,705,467 Accrued compensation 1,080,432 1,074,903 Stock based compensation 178,174 66,348 Credit carryforwards 52,592 71,910 Depreciation and amortization carryforwards (63,917 ) (71,054 ) Total 10,881,174 9,847,574 Less valuation allowance (10,881,174 ) (9,847,574 ) NET DEFERRED TAX ASSETS $ - $ -

Basic and Diluted Net Loss Pe_2

Basic and Diluted Net Loss Per Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for: Three-months ended September 30, 2019 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (1,433,626 ) 136,640,761 $ (0.01 ) Effect of dilutive securities—Common stock options, warrants, and convertible note - - - Diluted loss per share $ (1,433,626 ) 136,640,761 $ (0.01 ) Three-months ended September 30, 2018 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (928,888 ) 130,083,598 $ (0.01 ) Effect of dilutive securities—Common stock options, warrants, and convertible note - - - Diluted loss per share $ (928,888 ) 130,083,598 $ (0.01 ) Nine-months ended September 30, 2019 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (3,650,740 ) 135,516,490 (0.03 ) Effect of dilutive securities—Common stock options, warrants, and convertible note - - - Diluted loss per share $ (3,650,740 ) 135,516,490 (0.03 ) Nine-months ended September 30, 2018 (Unaudited) Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (3,076,873 ) 125,271,516 $ (0.02 ) Effect of dilutive securities—Common stock options, warrants, and convertible note - - - Diluted loss per share $ 3,076,873 125,271,516 $ (0.02 )	The following table sets forth the computation of the Company’s basic and diluted net loss per share for the years ended December 31: 2018 Net Loss Shares Per share Basic loss per share $ (4,024,222 ) 127,304,856 $ (0.03 ) Effect of dilutive securities—Common stock options and warrants - - - Diluted loss per share $ (4,024,222 ) 127,304,856 $ (0.03 ) 2017 Net Loss Shares Per share Basic loss per share $ (1,985,234 ) 99,951,385 $ (0.02 ) Effect of dilutive securities—Common stock options and warrants - - - Diluted loss per share $ (1,985,234 ) 99,951,385 $ (0.02 )
Schedule of Shares of Common Stock Equivalents Were Excluded from the Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended: September 30, 2019 September 30, 2018 (Unaudited) (Unaudited) Convertible notes 9,490,186 - Common stock options 40,438,425 39,496,761 Common stock warrants 102,758,031 118,148,846 Total common stock equivalents 152,686,642 157,645,607	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the years ended December 31: 2018 2017 Common stock options 40,496,761 38,213,427 Common stock warrants 118,046,862 127,434,122 Total common stock equivalents 158,543,623 165,647,549

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2018
Leases [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum lease payments are as follows for the years ended December 31: 2019 $ 17,868 2020 17,868 2021 1,489 $ 37,225

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Summary of Convertible Notes with Lenders	Each of these notes were issued with detachable five-year warrants to purchase shares of common stock as set forth in the table below. Issuance Date Principal Amount Original Issue Discount Gross Proceeds Note Conversion Price Per Share Number of Shares Underlying Warrants Warrant Exercise Price Per Share October 3, 2019 $ 27,174 $ 2,174 $ 25,000 $ 0.12 50,000 $ 0.12 October 10, 2019 27,174 2,174 25,000 0.12 50,000 0.12 October 23, 2019 108,696 8,696 100,000 0.12 250,000 250,000 0.15 0.20 October 29, 2019 27,174 2,174 25,000 0.12 50,000 0.12 November 8, 2019 16,304 1,304 15,000 0.07 30,000 0.07 Total $ 206,522 $ 16,522 $ 190,000 $ 0.07-0.12 680,000 $ 0.07-0.20 Issuance Date Principal Amount Original Issue Discount Gross Proceeds Note Conversion Price Per Share Number of Shares Underlying Warrants Warrant Exercise Price Per Share October 16, 2019 $ 217,391 $ 17,391 $ 200,000 $ 0.07 400,000 $ 0.07

Company Background (Details Nar

Company Background (Details Narrative) - USD ($)	Aug. 14, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Net losses		$ (1,433,626)	$ (928,888)	$ (3,650,740)	$ (3,076,873)	$ (4,024,222)	$ (1,985,234)
Accumulated deficit		$ (65,594,058)		(65,594,058)		(61,943,318)	(57,919,096)
Additional capital raised through equity				245,000	$ 704,375	$ 1,244,037	$ 4,138,435
Additional capital raised through debt				2,625,000
Proceeds from public offering of common stock and warrants	$ 15,000,000
Current Stockholders [Member]
Additional capital raised through equity				245,000
Related Party [Member]
Additional capital raised through debt				$ 2,325,000

Company Background (Details N_2

Company Background (Details Narrative) (10-K) - USD ($)	Jul. 27, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Net losses		$ (1,433,626)	$ (928,888)	$ (3,650,740)	$ (3,076,873)	$ (4,024,222)	$ (1,985,234)
Accumulated deficit		$ (65,594,058)		$ (65,594,058)		(61,943,318)	$ (57,919,096)
Stock issuance costs						196,006
Stock issuance costs, net offering						$ 1,244,037
Warrant [Member]
Proceeds from warrants issuances	$ 1,440,043
Cashless exercise of warrants	9,600,000					101,984	392,047

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) (10-K) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Jan. 02, 2019
Cash equivalents
Federal deposit insurance					0	1,988,139
Accounts receivable	$ 185,419		$ 185,419		157,082	37,243
Allowance for accounts receivable
Inventory reserves
Asset impairment charge
Shipping and handling costs					21,603	10,366
Sales taxes					3,329	5,132
Research and development costs	145,273	$ 86,115	250,141	$ 214,093	269,077	97,479
Advertising expenses					$ 364,306	84,317
Minimum percentage of income tax benefit					50.00%
Unrecognized tax benefit
Operating lease, right-to-use asset	$ 22,015		$ 22,015				$ 35,000
Operating lease liability							$ 35,000
Maximum [Member]
Federal deposit insurance					$ 250,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Depreciation of Estimated Useful Lives (Details) (10-K)	12 Months Ended
	Dec. 31, 2018
Furniture and Office Equipment [Member]
Estimated useful lives	7 years
Research and Development Equipment [Member] | Minimum [Member]
Estimated useful lives	3 years
Research and Development Equipment [Member] | Maximum [Member]
Estimated useful lives	7 years
Information Technology Equipment [Member]
Estimated useful lives	5 years
Software [Member]
Estimated useful lives	3 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source and Geographical Location (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Total revenue	$ 229,142	$ 549,540	$ 439,505	$ 1,134,899	$ 1,510,875	$ 610,323
United States [Member]
Total revenue			439,505	1,118,486	1,494,462	610,323
Hong Kong [Member]
Total revenue				$ 16,413	$ 16,413

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source and Geographical Location (Details) (10-K) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Total revenue	$ 229,142	$ 549,540	$ 439,505	$ 1,134,899	$ 1,510,875	$ 610,323
United States [Member]
Total revenue			439,505	1,118,486	1,494,462	610,323
Hong Kong [Member]
Total revenue				$ 16,413	$ 16,413

Inventories (Details Narrative)

Inventories (Details Narrative) (10-K) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 774,588	$ 1,383,630	$ 98,937

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished goods	$ 533,139	$ 96,750	$ 240,917
Raw materials	774,588	1,383,630	98,937
Total inventories	$ 1,307,727	$ 1,480,380	$ 340,425

Inventories - Schedule of Inv_2

Inventories - Schedule of Inventories (Details) (10-K) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished goods	$ 533,139	$ 96,750	$ 240,917
Raw materials	774,588	1,383,630	98,937
Packing supplies and materials			571
Total inventories	$ 1,307,727	$ 1,480,380	$ 340,425

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) (10-K) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,901	$ 5,854

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) (10-K) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Total property and equipment, net		$ 1,901
Information Technology Equipment [Member]
Information technology equipment		31,892
Less accumulated depreciation		(29,991)
Total property and equipment, net		$ 1,901

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)PatentApplicationsVehicle	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)Vehicle	Dec. 31, 2017USD ($)
Patent, amortization period			15 years		15 years
Amortization expense	$ 10,074	$ 6,717	$ 29,102	$ 21,952	$ 28,669	$ 23,568
Loss of abandonment of patents	$ 36,205		$ 36,205
Patents, units			29		28
Patents expiration date			Patents will expire beginning in 2023 through 2028		Patents will expire beginning in 2023 through 2028
Number of patent application pending | Vehicle			3
United States [Member]
Patents, units			14		14
Number of patent application pending			2		1
Europe, Canada, China, India, Japan, and Hong Kong [Member]
Patents, units			15		14
Europe and Brazil [Member]
Number of patent application pending			2		2

Intangible Assets, Net (Detai_2

Intangible Assets, Net (Details Narrative) (10-K)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)PatentApplicationsVehicle	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)Vehicle	Dec. 31, 2017USD ($)
Patent, amortization period			15 years		15 years
Amortization expense | $	$ 10,074	$ 6,717	$ 29,102	$ 21,952	$ 28,669	$ 23,568
Patents, units			29		28
Patents expiration date			Patents will expire beginning in 2023 through 2028		Patents will expire beginning in 2023 through 2028
Number of patent application pending | Vehicle			3
United States [Member]
Patents, units			14		14
Number of patent application pending			2		1
Europe, Canada, China, India, Japan, and Hong Kong [Member]
Patents, units			15		14
Europe and Brazil [Member]
Number of patent application pending			2		2

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 613,943	$ 578,326	$ 493,027
Less accumulated amortization	(321,614)	(292,512)	(263,843)
Patents, Total	292,329	285,814	229,184
Patents pending	135,292	148,720	197,426
Total intangible assets, net	$ 427,621	$ 434,534	$ 426,610

Intangible Assets, Net - Sche_2

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) (10-K) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 613,943	$ 578,326	$ 493,027
Less accumulated amortization	(321,614)	(292,512)	(263,843)
Patents, Total	292,329	285,814	229,184
Patents pending	135,292	148,720	197,426
Total intangible assets, net	$ 427,621	$ 434,534	$ 426,610

Accrued Separation Costs (Detai

Accrued Separation Costs (Details Narrative) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Aug. 09, 2016
Accrued compensation expenses				$ 118,635
Accrued separation costs, outstanding	$ 94,885
Accrued separation costs, current	$ 9,000	$ 9,000
Separation Agreement [Member]
Accrued compensation expenses				$ 118,635

Accrued Separation Costs (Det_2

Accrued Separation Costs (Details Narrative) (10-K)	Aug. 09, 2016USD ($)
Payables and Accruals [Abstract]
Accrued compensation expenses	$ 118,635

Accrued Separation Costs - Sche

Accrued Separation Costs - Schedule of Accrued Payroll and Payroll Related Expenses (Details) (10-K)	12 Months Ended
	Dec. 31, 2018USD ($)
Payables and Accruals [Abstract]
2019	$ 9,000
2020	9,000
2021	12,000
2022	12,000
2023	18,000
Thereafter	41,635
Accrued Separation Costs, gross	101,635
Less current portion	(9,000)
Accrued Separation Costs, net	$ 92,635

Related Party Notes Payable (De

Related Party Notes Payable (Details Narrative)	3 Months Ended	9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)
Interest charges	$ 45,925	$ 101,385
Notes Payable [Member]
Accrued and payable	$ 31,111	$ 31,111

Related Party Notes Payable - S

Related Party Notes Payable - Schedule of Related Party Notes Payable (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Total notes payable	$ 1,575,000
Less current portion	(575,000)
Long term notes payable	1,000,000
Inventory Financing [Member]
Total notes payable	1,000,000
Officer Loan [Member]
Total notes payable	75,000
Promissory Note [Member]
Total notes payable	$ 500,000

Related Party Notes Payable -_2

Related Party Notes Payable - Schedule of Related Party Notes Payable (Details) (Parenthetical) - USD ($)	Jun. 26, 2019	May 20, 2019	Jan. 11, 2019	Jul. 10, 2019
Inventory Financing [Member]
Line of credit			$ 1,000,000
Line of credit facility, interest rate			12.00%
Inventory Financing [Member] | Minimum [Member]
Ownership percentage			5.00%
Officer Loan [Member]
Debt instrument description	On June 26, 2019, the Company borrowed $75,000 from the Chief Executive Officer of the Company with principal and interest due on August 26, 2019, which was subsequently extended to December 31, 2019.
Officer Loan [Member] | Chief Executive Officer [Member]
Loan borrowed	$ 75,000
Debt instrument, interest rate	4.50%
Promissory Note [Member]
Loan borrowed				$ 100,000
Note payable		$ 400,000
Debt instrument, interest rate				12.00%
Debt instrument description		This note accrues interest at the rate of 12% per annum, is unsecured, and originally matured on August 20, 2019, which was subsequently extended to June 30, 2020.
Promissory Note [Member] | Minimum [Member]
Ownership percentage		5.00%

Related Party Notes Payable -_3

Related Party Notes Payable - Schedule of Related Party Future Maturities of Notes Payable (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Total	$ 750,000
Related Party Notes Payable [Member]
2020	575,000
2021
2022	1,000,000
Total	$ 1,575,000

Related Party Convertible Not_3

Related Party Convertible Note Payable (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Original issue discount	$ 65,217	$ 65,217
Interest charges incurred	45,925	101,385
Related Party Convertible Note Payable [Member]
Original issue discount	351,267	351,267
Interest expense	73,898	73,898
Interest charges incurred	13,222	13,222
Interest accrued and payable	$ 5,360	$ 5,360

Related Party Convertible Not_4

Related Party Convertible Note Payable - Schedule of Related Party Convertible Note Payable (Details) - USD ($)	Sep. 30, 2019	Jul. 19, 2019	Dec. 31, 2018
Total notes payable	$ 815,217
Less original issue discounts	(65,217)
Related party convertible note payable, net	750,000
Less conversion rights and warrant discounts	(286,050)
Plus amortization of discounts	73,898
Total convertible notes payable, net	537,848
Convertible Note 2019 - 02 [Member]
Total notes payable	$ 815,217
Less original issue discounts		$ (65,217)

Related Party Convertible Not_5

Related Party Convertible Note Payable - Schedule of Related Party Convertible Note Payable (Details) (Parenthetical) - USD ($)	Nov. 08, 2019	Jul. 19, 2019	Sep. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
Original issue discount			$ 65,217
Warrants price per share					$ 0.625
Convertible Note 2019 - 02 [Member]
Convertible notes payable issued		$ 815,217
Original issue discount		65,217
Exchange of convertible notes payable		$ 750,000
Debt instrument, interest rate		8.00%
Debt instrument, maturity date		Jun. 30, 2020
Debt instrument, conversion price		$ 0.12
Convertible Note 2019 - 02 [Member] | Detachable Warrant [Member]
Warrants to purchase common stock		1,500,000
Warrants price per share		$ 0.12
Additional discount on convertible note		$ 286,050
Convertible Note 2019 - 02 [Member] | Subsequent Event [Member]
Debt instrument, conversion price	$ 0.07
Debt instrument, discount offering price percentage	25.00%
Adjusted exercise price per share	$ 0.07
Convertible Note 2019 - 02 [Member] | Minimum [Member] | Subsequent Event [Member]
Convertible notes payable issued	$ 5,000,000

Related Party Convertible Not_6

Related Party Convertible Note Payable - Schedule of Related Party Future Maturities of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Total	$ 750,000
Related Party Convertible Note [Member]
2020	815,217
Total	$ 815,217

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Original issue discount	$ 65,217	$ 65,217
Interest charges incurred	45,925	101,385
Convertible Note [Member]
Original issue discount	111,704	111,704
Interest expense	31,696	55,358
Interest charges incurred	4,496	7,537
Interest accrued and payable	$ 7,537	$ 7,537

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Total notes payable	$ 815,217
Less conversion rights and warrant discounts	(286,050)
Plus amortization of discounts	73,898
Convertible Note 2019 - 01 [Member]
Total notes payable	150,000
Convertible Note 2019 - 03 [Member]
Total notes payable	108,696
Convertible Note 2019 - 04 [Member]
Total notes payable	54,348
Convertible Note [Member]
Total notes payable	313,044
Less original issue discounts	(13,044)
Related party convertible note payable, net	300,000
Less conversion rights and warrant discounts	(98,660)
Plus amortization of discounts	55,358
Total convertible notes payable, net	$ 256,698

Convertible Notes Payable - S_2

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Sep. 25, 2019	Sep. 04, 2019	Apr. 18, 2019	Nov. 08, 2019	Sep. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
Warrant price per share							$ 0.625
Original issue discount					$ 65,217
Convertible Note 2019 - 01 [Member]
Convertible notes payable issued			$ 150,000
Debt instrument, interest rate			10.00%
Debt instrument, maturity date			Dec. 31, 2019
Debt instrument, conversion price			$ 0.12
Convertible Note 2019 - 01 [Member] | Detachable Warrant [Member]
Warrants to purchase common stock			500,000
Warrant price per share			$ 0.20
Additional discount on convertible note			$ 83,300
Convertible Note 2019 - 01 [Member] | Subsequent Event [Member]
Adjusted exercise price per share				$ 0.07
Convertible Note 2019 - 03 [Member]
Convertible notes payable issued		$ 108,696
Debt instrument, interest rate		8.00%
Debt instrument, maturity date		Jun. 30, 2020
Debt instrument, conversion price		$ 0.12
Original issue discount		$ 8,696
Exchange of convertible notes payable		$ 100,000
Debt instrument, amortized period		36 months
Convertible Note 2019 - 03 [Member] | Detachable Warrant [Member]
Warrants to purchase common stock		200,000
Warrant price per share		$ 0.12
Additional discount on convertible note		$ 11,170
Convertible Note 2019 - 04 [Member]
Convertible notes payable issued	$ 54,348
Debt instrument, interest rate	8.00%
Debt instrument, maturity date	Jun. 30, 2020
Debt instrument, conversion price	$ 0.12
Original issue discount	$ 4,348
Exchange of convertible notes payable	$ 50,000
Debt instrument, amortized period	36 months
Convertible Note 2019 - 04 [Member] | Detachable Warrant [Member]
Warrants to purchase common stock	100,000
Warrant price per share	$ 0.12
Additional discount on convertible note	$ 4,190

Convertible Notes Payable - S_3

Convertible Notes Payable - Schedule of Future Maturities of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Total	$ 750,000
Convertible Note [Member]
2020	313,044
Total	$ 313,044

Derivative Financial Instrume_3

Derivative Financial Instrument (Details Narrative)	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)Vehicle	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)Vehicle	Sep. 30, 2018USD ($)
Derivative liabilities and convertible note discounts	$ 243,275		$ 243,275
Derivative liabilities	246,414		246,414
Loss on fair value of derivative liabilities	$ (20,524)		$ (3,139)
Expected Dividend Yield [Member]
Derivative liabilities, measurement input | Vehicle	0		0

Derivative Financial Instrume_4

Derivative Financial Instruments - Schedule of Fair Value Assumptions Related to Option Issued (Details)	9 Months Ended
	Sep. 30, 2019USD ($)Vehicle
Derivative liabilities	$ 246,414
Expected Dividend Yield [Member]
Derivative liabilities, measurement input | Vehicle	0
Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative liabilities
Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative liabilities
Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative liabilities	$ 246,414
Convertible Note [Member] | Expected Dividend Yield [Member]
Derivative liabilities, measurement input	0
Convertible Note [Member] | Risk Free Interest Rate [Member] | Minimum [Member]
Derivative liabilities, measurement input	0.0175
Convertible Note [Member] | Risk Free Interest Rate [Member] | Maximum [Member]
Derivative liabilities, measurement input	0.0244
Convertible Note [Member] | Volatility [Member] | Minimum [Member]
Derivative liabilities, measurement input	1.02
Convertible Note [Member] | Volatility [Member] | Maximum [Member]
Derivative liabilities, measurement input	1.37
Convertible Note [Member] | Expected Term [Member]
Derivative liabilities, expected term	1 year

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)	Jul. 27, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Sold securities in a self-directed offering, aggregate amount		$ 245,000	$ 704,375	$ 1,244,037	$ 4,138,435
Warrant price per share						$ 0.625
Number of common stock issued	9,600,286
Stock issuance costs				$ 196,006
Common stock, shares outstanding		137,261,594		133,888,573	122,674,516
Warrant Exchange Offering [Member]
Sold securities in a self-directed offering, aggregate amount	$ 1,440,043
Warrants to purchase of common stock shares	9,600,000
Warrant price per share						0.625
Cash payment, price per share						$ 0.15
Number of common stock issued	9,600,286
Stock issuance costs	$ 196,006
Proceeds from issuance of common stock, net of issuance costs	$ 1,244,037
Self-Directed Stock Issuance [Member]
Number of restricted common stock					2,237,500
Self-Directed Stock Issuance [Member] | Existing Stockholders [Member]
Sold securities in a self-directed offering, aggregate amount		$ 245,000
Issuance of stock per share		$ 0.30
Sale of stock, description of transaction		Each $0.30 unit consisted of 2 shares of restricted common stock (1,633,330 shares) and a five-year warrant to purchase 1 share of restricted common stock (816,665 warrant shares) at $0.20 per share.
Number of restricted common stock		1,633,330
Warrants to purchase of common stock shares		816,665
Warrants term		5 years
Self-Directed Stock Issuance [Member] | Existing Stockholders [Member] | Restricted Common Stock [Member]
Issuance of stock per share		$ 0.20

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details Narrative) (10-K) - USD ($)	Jul. 27, 2018	May 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Warrant price per share							$ 0.625
Share price							0.15
Number of common stock issued	9,600,286
Stock issuance costs					$ 196,006
Stock issuance costs, net offering					1,244,037
Sold securities in a self-directed offering, aggregate amount			$ 245,000	$ 704,375	$ 1,244,037	$ 4,138,435
Common stock, shares outstanding			137,261,594		133,888,573	122,674,516
Equity Purchase Agreement [Member]
Number of common stock shares sold						567,644
Proceeds from sale of common stock						$ 60,000
Restricted Stock One [Member]
Restricted common stock price per share						$ 0.08
Warrants to purchase of common stock shares						2,237,500
Warrants term						5 years
Restricted Stock Two [Member]
Restricted common stock price per share						$ 0.12
Warrants to purchase of common stock shares						2,237,500
Warrants term						5 years
Restricted Stock Three [Member]
Restricted common stock price per share						$ 0.16
Warrants to purchase of common stock shares						2,237,500
Warrants term						5 years
Restricted Stock Four [Member]
Restricted common stock price per share						$ 0.12
Warrants to purchase of common stock shares						31,453,788
Warrants term						5 years
Restricted Stock Five [Member]
Restricted common stock price per share						$ 0.12
Warrants to purchase of common stock shares						31,453,788
Warrants term						5 years
Restricted Stock Six [Member]
Restricted common stock price per share						$ 0.30
Warrants to purchase of common stock shares						416,595
Warrants term						5 years
Restricted Stock Seven [Member]
Restricted common stock price per share						$ 0.30
Warrants to purchase of common stock shares						416,595
Warrants term						5 years
Restricted Common Stock [Member]
Sold securities in a self-directed offering, aggregate amount		$ 44,700
Issuance of stock per share		$ 0.08
Conversion stock, description		Each unit consisted of 1 share of restricted common stock (558,750 shares), a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.08 per share, a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.16 per share.
Number of restricted common stock		558,750
Restricted Common Stock One [Member]
Restricted common stock price per share		$ 0.08
Warrants to purchase of common stock shares		558,750
Warrants term		5 years
Restricted Common Stock Two [Member]
Restricted common stock price per share		$ 0.12
Warrants to purchase of common stock shares		558,750
Warrants term		5 years
Restricted Common Stock Three [Member]
Restricted common stock price per share		$ 0.16
Warrants to purchase of common stock shares		558,750
Warrants term		5 years
Warrant [Member]
Warrant price per share							$ 0.625
Cashless exercise of warrants	9,600,000
Proceeds from warrants issuances	$ 1,440,043
Warrants to purchase of common stock shares	9,600,000				101,984	392,047
Self Directed Stock Issuance One [Member]
Sold securities in a self-directed offering, aggregate amount						$ 179,000
Issuance of stock per share						$ 0.08
Self Directed Stock Issuance Two [Member]
Sold securities in a self-directed offering, aggregate amount						$ 3,774,456
Issuance of stock per share						$ 0.12
Self Directed Stock Issuance Three [Member]
Sold securities in a self-directed offering, aggregate amount						$ 124,979
Issuance of stock per share						$ 0.30
Self-Directed Stock Issuance [Member]
Conversion stock, description						Each $0.08 unit consisted of 1 share of restricted common stock (2,237,500 shares), a five-year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.08 per share, a five-year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.16 per share. Each $0.12 unit consisted of 1 share of restricted common stock (31,453,788 shares) and a five-year warrant to purchase 1 share of restricted common stock (31,453,788 warrant shares) at $0.12 per share. Each $0.30 unit consisted of 1 share of restricted common stock (416,595 shares) and a five-year warrant to purchase 1 share of restricted common stock (416,595 warrant shares) at $0.30 per share.
Number of restricted common stock						2,237,500

Stock Grants (Details Narrative

Stock Grants (Details Narrative) - USD ($)	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Aug. 08, 2017	Apr. 10, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2018
Number of shares granted during period								2,833,334	2,161,458
Stock-based compensation expense						$ 257,875	$ 233,125	$ 650,271
Share price										$ 0.15
Restricted Common Stock [Member] | Consultant One [Member]
Number of shares granted during period					100,000
Stock-based compensation expense						0	5,750
Share price					$ 0.23
Restricted Common Stock [Member] | Consultant Two [Member]
Number of shares granted during period				100,000
Stock-based compensation expense						$ 0	$ 4,375
Share price				$ 0.175
Share-based payment forfeiture and vesting rights, percentage				25.00%
Restricted Common Stock [Member] | Directors [Member]
Number of shares granted during period						1,627,191	906,774
Stock-based compensation expense						$ 262,500	$ 200,000
Restricted Common Stock [Member] | Consultants [Member]
Number of shares granted during period	37,500	37,500	112,500			37,500
Stock-based compensation expense						$ 14,400		$ 22,500
Share price	$ 0.125	$ 0.17	$ 0.20			$ 0.089		$ 0.20

Stock Grants (Details Narrati_2

Stock Grants (Details Narrative) (10-K) - USD ($)	Sep. 01, 2017	Aug. 08, 2017	Apr. 10, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Restricted common stock, value							$ 44,700
Stock compensation expense				$ 257,875	$ 233,125	$ 650,271
Director [Member]
Restricted common stock, shares						1,344,274	793,025
Restricted common stock, value						$ 287,500	$ 150,000
Consultant [Member]
Restricted common stock, shares		100,000	100,000			112,500
Restricted common stock, per share		$ 0.175	$ 0.23			$ 0.20
Stock compensation expense						$ 22,500
Share-based payment forfeiture and vesting rights, percentage	25.00%
Consultant [Member] | April 10, 2017 [Member]
Stock compensation expense							17,250
Consultant [Member] | August 8, 2017 [Member]
Stock compensation expense						$ 10,125	$ 13,125

Stock Option Plans (Details Nar

Stock Option Plans (Details Narrative) - $ / shares	Jul. 27, 2018	Feb. 07, 2014	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 04, 2018	Apr. 16, 2015
Options default term			4 years 1 month 6 days	4 years 11 months 23 days	5 years 11 months 8 days
Dividend yield			0.00%	0.00%	0.00%
Number of common stock shares issued	9,600,286
Stock Option Exercise [Member]
Number of common stock shares issued				156,997	645,288
Cashless exercise of a stock option, shares				100,000	100,000
Common stock per share				$ 0.06	$ 0.155
Number of common stock withheld with aggregate exercise price				43,003	124,712
Stock Option Exercise One [Member]
Cashless exercise of a stock option, shares				50,000	45,000
Common stock per share				$ 0.06	$ 0.06
Stock Option Exercise Two [Member]
Cashless exercise of a stock option, shares				50,000	625,000
Common stock per share				$ 0.06	$ 0.06
2014 Equity Compensation Plan [Member]
Number of reserved for future issuance		30,420,148				50,420,148
2014 Equity Compensation Plan [Member] | Majority Stockholders [Member]
Number of reserved for future issuance							15,000,000
2014 Equity Compensation Plan [Member] | Stockholders [Member]
Number of reserved for future issuance						5,000,000
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member]
Options default term		10 years		10 years
Generally vest term		4 years		4 years
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Maximum [Member]
Percentage price per share of options granted of fair market value				100.00%
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Employees [Member] | Maximum [Member]
Percentage price per share of options granted of fair market value		100.00%
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | 10% Stockholder [Member] | Maximum [Member]
Percentage price per share of options granted of fair market value		110.00%
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Employees, Directors, Advisors and Consultants [Member] | Maximum [Member] | Non-statutory Stock Options and Restricted Stock [Member]
Percentage price per share of options granted of fair market value		100.00%

Stock Option Plans (Details N_2

Stock Option Plans (Details Narrative) (10-K) - USD ($)	Jul. 27, 2018	Feb. 07, 2014	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Apr. 16, 2015
Options default term			4 years 1 month 6 days	4 years 11 months 23 days	5 years 11 months 8 days
Dividend yield				$ 0
Number of common stock shares issued	9,600,286
Stock Option Exercise [Member]
Number of common stock shares issued				156,997	645,288
Cashless exercise of a stock option, shares				100,000	100,000
Common stock per share				$ 0.06	$ 0.155
Number of common stock withheld with aggregate exercise price				43,003	124,712
Stock Option Exercise One [Member]
Cashless exercise of a stock option, shares				50,000	45,000
Common stock per share				$ 0.06	$ 0.06
Stock Option Exercise Two [Member]
Cashless exercise of a stock option, shares				50,000	625,000
Common stock per share				$ 0.06	$ 0.06
2014 Equity Compensation Plan [Member]
Aggregate number of shares issuable under this plan		30,420,148
Shares authorized				50,420,148		15,000,000
Additional shares authorized				5,000,000
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member]
Percentage of stock option granted to stockholders				10.00%
Options default term		10 years		10 years
Generally vest term		4 years		4 years
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Maximum [Member]
Percentage granted to employees at a price per share				100.00%
Percentage exercise price per share				110.00%
Percentage restricted stock to related parties price per share				100.00%

Stock Option Plans - Schedule o

Stock Option Plans - Schedule of Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Options Outstanding, Beginning balance	40,496,761	38,213,427	36,821,969
Options Exercisable, Beginning balance	37,157,179	36,213,427	36,771,969
Options, Canceled	(58,336)	(350,000)
Options, Granted		2,833,334	2,161,458
Options, Exercised		(200,000)	(770,000)
Options, Forfeited
Options Outstanding, Ending balance	40,438,425	40,496,761	38,213,427
Options Exercisable, Ending balance	38,130,093	37,157,179	36,213,427
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.40	$ 0.41	$ 0.41
Weighted Average Exercise Price, Exercisable, Beginning balance	0.41	0.41	0.41
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending balance	0.40	0.40	0.41
Weighted Average Exercise Price, Exercisable, Ending balance	$ 0.41	$ 0.41	$ 0.41
Weighted Average Remaining Contractual Term in Years, Outstanding Beginning	4 years 6 months 7 days	5 years 2 months 23 days	5 years 11 months 8 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Beginning	4 years 1 month 6 days	4 years 11 months 23 days	5 years 11 months 8 days
Weighted Average Remaining Contractual Term in Years, Outstanding Ending	3 years 9 months 7 days	4 years 6 months 7 days	5 years 2 months 23 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Ending	3 years 5 months 23 days	4 years 1 month 6 days	4 years 11 months 23 days
Aggregate Intrinsic Value, Outstanding Beginning balance	$ 986,808	$ 562,456	$ 301,273
Aggregate Intrinsic Value, Exercisable Beginning balance	966,808	562,456	299,273
Aggregate Intrinsic Value, Outstanding Ending balance	149,089	986,808	562,456
Aggregate Intrinsic Value, Exercisable Ending balance	$ 149,089	$ 966,808	$ 562,456

Stock Option Plans - Schedule_2

Stock Option Plans - Schedule of Stock Option Activity (Details) (10-K) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Options Outstanding, Beginning balance	40,496,761	38,213,427	36,821,969
Options Exercisable, Beginning balance	37,157,179	36,213,427	36,771,969
Options, Canceled	(58,336)	(350,000)
Options, Granted		2,833,334	2,161,458
Options, Exercised		(200,000)	(770,000)
Options, Forfeited
Options Outstanding, Ending balance	40,438,425	40,496,761	38,213,427
Options Exercisable, Ending balance	38,130,093	37,157,179	36,213,427
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.40	$ 0.41	$ 0.41
Weighted Average Exercise Price, Exercisable, Beginning balance	0.41	0.41	0.41
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending balance	0.40	0.40	0.41
Weighted Average Exercise Price, Exercisable, Ending balance	$ 0.41	$ 0.41	$ 0.41
Weighted Average Remaining Contractual Term in Years, Outstanding Beginning	4 years 6 months 7 days	5 years 2 months 23 days	5 years 11 months 8 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Beginning	4 years 1 month 6 days	4 years 11 months 23 days	5 years 11 months 8 days
Weighted Average Remaining Contractual Term in Years, Outstanding Ending	3 years 9 months 7 days	4 years 6 months 7 days	5 years 2 months 23 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Ending	3 years 5 months 23 days	4 years 1 month 6 days	4 years 11 months 23 days
Aggregate Intrinsic Value, Outstanding Beginning balance	$ 986,808	$ 562,456	$ 301,273
Aggregate Intrinsic Value, Exercisable Beginning balance	966,808	562,456	299,273
Aggregate Intrinsic Value, Outstanding Ending balance	149,089	986,808	562,456
Aggregate Intrinsic Value, Exercisable Ending balance	$ 149,089	$ 966,808	$ 562,456

Stock Option Plans - Schedule_3

Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Non-vested, Options Outstanding, Beginning balance	3,339,582	2,000,000	50,000
Non-vested, Options Granted		2,833,334	2,161,458
Non-vested, Options Vested	(972,914)	(1,143,752)	(211,458)
Non-vested, Options Canceled	(58,336)	(350,000)
Non-vested, Options Outstanding, Ending balance	2,308,332	3,339,582	2,000,000

Stock Option Plans - Schedule_4

Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) (10-K) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Non-vested, Options Outstanding, Beginning balance	3,339,582	2,000,000	50,000
Non-vested, Options Granted		2,833,334	2,161,458
Non-vested, Options Vested	(972,914)	(1,143,752)	(211,458)
Non-vested, Options Canceled	(58,336)	(350,000)
Non-vested, Options Outstanding, Ending balance	2,308,332	3,339,582	2,000,000

Stock Option Plans - Schedule_5

Stock Option Plans - Schedule of Fair Value Assumptions (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Dividend yield	0.00%	0.00%	0.00%
Risk-free rate, minimum	2.38%	2.38%
Risk-free rate, maximum	3.04%	3.04%
Expected volatility, minimum	214.00%	214.00%
Expected volatility, Maximum	226.00%	226.00%
Minimum [Member]
Expected term	3 years	3 years	5 years
Maximum [Member]
Expected term	7 years	7 years	7 years

Stock Option Plans - Schedule_6

Stock Option Plans - Schedule of Fair Value Assumptions (Details) (10-K)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Risk-free rate		2.38%	1.89%
Expected volatility		214.00%	221.00%
Expected term	3 years	3 years	5 years
Maximum [Member]
Risk-free rate		3.04%	2.26%
Expected volatility		226.00%	232.00%
Expected term	7 years	7 years	7 years

Stock Option Plans - Schedule_7

Stock Option Plans - Schedule of Recognized Stock Based Compensation Expense (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Service provider compensation	$ 133,125	$ 76,250	$ 124,896	$ 3,500
Employee compensation	124,750	156,875
Total	$ 257,875	$ 233,125	$ 650,271

Stock Option Plans - Schedule_8

Stock Option Plans - Schedule of Recognized Stock Based Compensation Expense (Details) (10-K) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Service provider compensation	$ 133,125	$ 76,250	$ 124,896	$ 3,500
Employee compensation			205,250	33,271
Director compensation				25,000
Total			$ 330,146	$ 61,771

Warrants (Details Narrative)

Warrants (Details Narrative)	Jul. 27, 2018USD ($)$ / sharesshares	Sep. 30, 2019USD ($)Vehicle$ / sharesshares	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)shares	Jun. 30, 2018$ / shares
Stock compensation expense		$ 257,875	$ 233,125	$ 650,271
Warrant price per share | $ / shares						$ 0.625
Discount on convertible notes		65,217
Proceeds from the issuance of common stock		$ 245,000	704,375	1,244,037	$ 4,138,435
Number of common stock shares issued | shares	9,600,286
Stock issuance costs				196,006
Warrant Exchange Offering [Member]
Warrants to purchase of common stock shares | shares	9,600,000
Warrant price per share | $ / shares						0.625
Cash payment, price per share | $ / shares						0.15
Proceeds from the issuance of common stock	$ 1,440,043
Number of common stock shares issued | shares	9,600,286
Stock issuance costs	$ 196,006
Proceeds from issuance of common stock, net of issuance costs	$ 1,244,037
Warrant Exchange Offering [Member] | Investment Bankers [Member]
Warrants to purchase of common stock shares | shares	315,010
Warrant price per share | $ / shares	$ 0.21
Convertible Note Warrants [Member]
Warrants to purchase of common stock shares | shares		2,300,000
Warrants, term		5 years
Discount on convertible notes		$ 141,435
Convertible Note Warrants [Member] | Minimum [Member]
Warrant price per share | $ / shares		$ 0.12
Convertible Note Warrants [Member] | Maximum [Member]
Warrant price per share | $ / shares		$ 0.20
Warrant [Member]
Stock compensation expense				$ 0	$ 0
Warrants to purchase of common stock shares | shares	9,600,000			101,984	392,047
Warrant price per share | $ / shares						$ 0.625
Warrants expired | shares		18,405,496		101,984	392,047
Expected Dividend Yield [Member]
Warrants, measurement input | Vehicle		0

Warrants (Details Narrative) (1

Warrants (Details Narrative) (10-K) - USD ($)	Jul. 27, 2018	Jun. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Dividend yield					$ 0
Stock compensation expense			$ 257,875	$ 233,125	650,271
Number of common stock shares issued	9,600,286
Warrant price per share		$ 0.625
Number of common stock value issued						$ 60,000
Stock issuance costs					196,006
Stock issuance costs, net offering					$ 1,244,037
Common stock par value			$ 0.001		$ 0.001	$ 0.001
Investment Bankers [Member]
Issuance of shares issued for services					315,010
Common stock par value					$ 0.21
Warrant [Member]
Stock compensation expense					$ 0	$ 0
Cashless exercise of warrants	9,600,000
Warrant price per share		0.625
Cash payments		$ 0.15
Proceeds from warrants issuances	$ 1,440,043
Warrants to purchase an aggregate number of shares	9,600,000				101,984	392,047
Warrant Exercise [Member]
Number of common stock shares issued						233,217
Cashless exercise of warrants						298,000
Warrant price per share						$ 0.10
Aggregate fair market value of common stock withheld						64,783
Warrant Exercise One [Member]
Number of common stock shares issued						500,000
Cashless exercise of warrants						500,000
Warrant price per share						$ 0.08
Number of common stock value issued						$ 40,000

Warrants - Schedule of Stock Wa

Warrants - Schedule of Stock Warrants Activity (Details) - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Warrants, Outstanding, Beginning balance	118,046,862	127,434,122	88,365,036
Warrants, Exercisable, Beginning balance	118,046,862	127,434,122	88,365,036
Warrants, Canceled
Warrants, Granted	3,116,665	315,010	40,259,133
Warrants, Exercised		(9,600,286)	(798,000)
Warrants, Expired	(18,405,496)	(101,984)	(392,047)
Warrants, Outstanding, Ending balance	102,758,031	118,046,862	127,434,122
Warrants, Exercisable, Ending balance	102,758,031	118,046,862	127,434,122
Weighted Average Exercise Price, Outstanding, Beginning	$ 0.20	$ 0.24	$ 0.30
Weighted Average Exercise Price, Exercisable, Beginning	0.20	0.24	0.30
Weighted Average Exercise Price, Canceled/Expired
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending	0.13	0.20	0.24
Weighted Average Exercise Price, Exercisable, Ending	$ 0.13	$ 0.20	$ 0.24
Weighted Average Remaining Contractual Term in Years, Beginning Outstanding	2 years 3 months 26 days	3 years 1 month 24 days	3 years 6 months
Weighted Average Remaining Contractual Term in Years, Beginning Exercisable	2 years 3 months 26 days	3 years 1 month 24 days	3 years 6 months
Weighted Average Remaining Contractual Term in Years, Ending Outstanding	2 years 26 days	2 years 3 months 26 days	3 years 1 month 24 days
Weighted Average Remaining Contractual Term in Years, Ending Exercisable	2 years 26 days	2 years 3 months 26 days	3 years 1 month 24 days
Aggregate Intrinsic Value, Outstanding, Beginning	$ 7,848,637	$ 3,957,689	$ 543,770
Aggregate Intrinsic Value, Exercisable, Beginning	7,848,637	3,957,689	543,770
Aggregate Intrinsic Value, Outstanding, Ending	146,779	7,848,637	3,957,689
Aggregate Intrinsic Value, Exercisable, Ending	$ 146,779	$ 7,848,637	$ 3,957,689

Warrants - Schedule of Stock _2

Warrants - Schedule of Stock Warrants Activity (Details) (10-K) - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Warrants, Outstanding, Beginning balance	118,046,862	127,434,122	88,365,036
Warrants, Exercisable, Beginning balance	118,046,862	127,434,122	88,365,036
Warrants, Canceled
Warrants, Granted	3,116,665	315,010	40,259,133
Warrants, Exercised		(9,600,286)	(798,000)
Warrants, Forfeited	(18,405,496)	(101,984)	(392,047)
Warrants, Outstanding, Ending balance	102,758,031	118,046,862	127,434,122
Warrants, Exercisable, Ending balance	102,758,031	118,046,862	127,434,122
Weighted Average Exercise Price, Outstanding, Beginning	$ 0.20	$ 0.24	$ 0.30
Weighted Average Exercise Price, Exercisable, Beginning	0.20	0.24	0.30
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending	0.13	0.20	0.24
Weighted Average Exercise Price, Exercisable, Ending	$ 0.13	$ 0.20	$ 0.24
Weighted Average Remaining Contractual Term in Years, Beginning Outstanding	2 years 3 months 26 days	3 years 1 month 24 days	3 years 6 months
Weighted Average Remaining Contractual Term in Years, Beginning Exercisable	2 years 3 months 26 days	3 years 1 month 24 days	3 years 6 months
Weighted Average Remaining Contractual Term in Years, Ending Outstanding	2 years 26 days	2 years 3 months 26 days	3 years 1 month 24 days
Weighted Average Remaining Contractual Term in Years, Ending Exercisable	2 years 26 days	2 years 3 months 26 days	3 years 1 month 24 days
Aggregate Intrinsic Value, Outstanding, Beginning	$ 7,848,637	$ 3,957,689	$ 543,770
Aggregate Intrinsic Value, Exercisable, Beginning	7,848,637	3,957,689	543,770
Aggregate Intrinsic Value, Outstanding, Ending	146,779	7,848,637	3,957,689
Aggregate Intrinsic Value, Exercisable, Ending	$ 146,779	$ 7,848,637	$ 3,957,689

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 22, 2017	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Effective tax statutory rate	35.00%	21.00%	21.00%	21.00%	34.00%	21.00%	21.00%	34.00%
Effective tax statutory rate, description						On March 22, 2018, the Tax Cuts and Jobs Act ("TCJA") was enacted into law, which significantly changes existing U.S. tax law and includes numerous provisions that affect our business, such as reducing the U.S. federal statutory tax rate from 35% to 21% effective January 1, 2018.
Unrecognized tax benefits

Income Taxes (Details Narrati_2

Income Taxes (Details Narrative) (10-K) - USD ($)	Dec. 22, 2017	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Effective tax statutory rate	35.00%	21.00%	21.00%	21.00%	34.00%	21.00%		21.00%	34.00%
Provision for income taxes
Income tax offset percentage								80.00%
Reduced tax rate								21.00%
Deferred tax asset									3,800,000
Refundable tax credit									$ 17,253
Hawaii Income Tax Purposes [Member]
Operating loss carry forwards			$ 29,286,880					$ 29,286,880
Federal [Member]
Operating loss carry forwards			$ 36,950,157					$ 36,950,157

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Taxes Rate (Details) (10-K)	Dec. 22, 2017	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Tax provision (benefit) at Federal statutory rate	(35.00%)	(21.00%)	(21.00%)	(21.00%)	(34.00%)	(21.00%)	(21.00%)	(34.00%)
Accrued compensation							(0.28%)	(0.32%)
Stock based compensation							3.37%	4.15%
Depreciation and amortization							0.15%	0.59%
Other							0.07%	0.26%
Change in valuation allowance							17.69%	29.32%
Effective tax rate							0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) (10-K) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 9,633,893	$ 8,705,467
Accrued compensation	1,080,432	1,074,903
Stock based compensation	178,174	66,348
Credit carryforwards	52,592	71,910
Depreciation and amortization carryforwards	(63,917)	(71,054)
Total	10,881,174	9,847,574
Less valuation allowance	(10,881,174)	(9,847,574)
NET DEFERRED TAX ASSETS

Basic and Diluted Net Loss Pe_3

Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net loss (numerator) Basic loss per share, basic	$ (1,433,626)	$ (928,888)	$ (3,650,740)	$ (3,076,873)	$ (4,024,222)	$ (1,985,234)
Net loss (numerator) Effect of dilutive securities-Common stock options, warrants, and convertible note
Net loss (numerator) Diluted loss per share, diluted	$ (1,433,626)	$ (928,888)	$ (3,650,740)	$ (3,076,873)	$ (4,024,222)	$ (1,985,234)
Shares (Denominator) Basic loss per shares, basic	136,640,761	130,083,598	135,516,490	125,271,516	127,304,856	99,951,385
Shares (Denominator) Effect of dilutive securities-Common stock options, warrants, and convertible note
Shares (Denominator) Diluted loss per shares, diluted	136,640,761	130,083,598	135,516,490	125,271,516	127,304,856	99,951,385
Per share amount Basic loss per share, basic	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.03)	$ (0.02)
Per share amount Effect of dilutive securities-Common stock options, warrants, and convertible note
Per share amount Diluted loss per share, diluted	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.03)	$ (0.02)

Basic and Diluted Net Loss Pe_4

Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) (10-K) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net loss (numerator) Basic loss per share, basic	$ (1,433,626)	$ (928,888)	$ (3,650,740)	$ (3,076,873)	$ (4,024,222)	$ (1,985,234)
Net loss (numerator) Effect of dilutive securities-common stock options and warrants
Net loss (numerator) Diluted loss per share, diluted	$ (1,433,626)	$ (928,888)	$ (3,650,740)	$ (3,076,873)	$ (4,024,222)	$ (1,985,234)
Shares (denominator) Basic loss per shares, basic	136,640,761	130,083,598	135,516,490	125,271,516	127,304,856	99,951,385
Shares (denominator) Effect of dilutive securities-common stock options and warrants
Shares (denominator) Diluted loss per shares, diluted	136,640,761	130,083,598	135,516,490	125,271,516	127,304,856	99,951,385
Per share amount Basic loss per share, basic	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.03)	$ (0.02)
Per share amount Effect of dilutive securities-common stock options and warrants
Per share amount Diluted loss per share, diluted	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.03)	$ (0.02)

Basic and Diluted Net Loss Pe_5

Basic and Diluted Net Loss Per Share - Schedule of Shares of Common Stock Equivalents Were Excluded from the Computation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Total common stock equivalents excluded from the computation of diluted net loss per share	152,686,642	157,645,607	158,543,623	165,647,549
Common Stock Warrants [Member]
Total common stock equivalents excluded from the computation of diluted net loss per share	102,758,031	118,148,846	118,046,862	127,434,122
Convertible Notes [Member]
Total common stock equivalents excluded from the computation of diluted net loss per share	9,490,186
Common Stock Options [Member]
Total common stock equivalents excluded from the computation of diluted net loss per share	40,438,425	39,496,761	40,496,761	38,213,427

Basic and Diluted Net Loss Pe_6

Basic and Diluted Net Loss Per Share - Schedule of Computation of Diluted Net Income (Loss) Per Share (Details) (10-K) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Total common stock equivalents	152,686,642	157,645,607	158,543,623	165,647,549
Common Stock Warrants [Member]
Total common stock equivalents	102,758,031	118,148,846	118,046,862	127,434,122
Common Stock Options [Member]
Total common stock equivalents	40,438,425	39,496,761	40,496,761	38,213,427

Leases (Details Narrative)

Leases (Details Narrative)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2018USD ($)Vehicle	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 02, 2019USD ($)
Total monthly payment	$ 1,619
Lease expense						$ 21,196
Operating lease, right-to-use asset		$ 22,015		$ 22,015				$ 35,000
Operating lease liability								$ 35,000
ASU No. 2016-02 [Member]
Operating lease, right-to-use asset		22,015		22,015
Operating lease liability		$ 22,015		$ 22,015
Lease Settlement Agreement [Member] | Manoa Innovation Center [Member]
Lease, term		45 days		45 days
Rent expenses		$ 8,989	$ 8,760	$ 27,188	$ 29,662	$ 39,302	$ 29,690
Vehicle Lease Arrangement [Member]
Lease, term	3 years
Number of vehicles | Vehicle	3
Total monthly payment	$ 1,619
Lease expense		$ 4,964	$ 5,602	$ 16,520	$ 14,953

Leases (Details Narrative) (10-

Leases (Details Narrative) (10-K) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Total monthly payment	$ 1,619
Lease expense						$ 21,196
Lease Settlement Agreement [Member] | Manoa Innovation Center [Member]
Rent expenses		$ 8,989	$ 8,760	$ 27,188	$ 29,662	$ 39,302	$ 29,690

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments (Details) (10-K)	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 17,868
2020	17,868
2021	1,489
Future minimum lease payments	$ 37,225

Commitments (Details Narrative)

Commitments (Details Narrative) (10-K) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2019
Payment for license cost	$ 10,000
Percentage of royalties revenue	2.00%
License revenue
License payable	20,000	20,000
Employee settlement	50,000	50,000	$ 50,000
BASF Agreement And License [Member]
Royalties
Capsugel Agreement [Member]
Revenues

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 14, 2019	Dec. 31, 2018	Dec. 31, 2017	Nov. 08, 2019	Oct. 29, 2019	Oct. 23, 2019	Oct. 16, 2019	Oct. 10, 2019	Oct. 03, 2019
Debt instrument, conversion converted amount			$ 44,700
Subsequent Event [Member] | Convertible Notes [Member] | Detachable Warrant [Member]
Warrants term				5 years
Adjusted exercise price per share				$ 0.07
Subsequent Event [Member] | Convertible Notes [Member] | Lenders as Stockholders [Member]
Debt instrument, interest rate	8.00%
Debt instrument, maturity date	Jun. 30, 2020
Debt instrument, amortized period	36 months
Debt instrument, conversion price				0.07	$ 0.12	$ 0.12		$ 0.12	$ 0.12
Adjusted exercise price per share				$ 0.07
Subsequent Event [Member] | Convertible Notes [Member] | Lenders as Stockholders [Member] | Minimum [Member]
Debt instrument, conversion price	$ 0.07
Subsequent Event [Member] | Convertible Notes [Member] | Lenders as Stockholders [Member] | Detachable Warrant [Member]
Warrants term	5 years
Subsequent Event [Member] | Convertible Notes [Member] | Lender [Member]
Debt instrument, interest rate	8.00%
Debt instrument, maturity date	Jun. 30, 2020
Debt instrument, conversion price	$ 0.12						$ 0.07
Subsequent Event [Member] | Convertible Notes [Member] | Lender [Member] | Minimum [Member]
Ownership percentage	5.00%
Debt instrument, conversion converted amount	$ 5,000,000
Debt instrument convertible threshold percentage	25.00%

Subsequent Events (Details Na_2

Subsequent Events (Details Narrative) (10-K) - USD ($)	Feb. 22, 2019	Feb. 07, 2019	Jan. 11, 2019	Jul. 27, 2018	Sep. 30, 2019	Mar. 27, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Number of common stock shares issued				9,600,286
Common stock, par value					$ 0.001		$ 0.001		$ 0.001
Common stock, shares issued					137,261,594		133,888,573		122,674,516
Common stock, shares outstanding					137,261,594		133,888,573		122,674,516
Warrant price per share								$ 0.625
Warrant [Member]
Warrant price per share								$ 0.625
Subsequent Event [Member]
Line of credit facility, interest rate			12.00%
Aggregate unpaid principal amount under credit facility						$ 1,000,000
Number of common stock shares issued	133,332	167,730,236
Common stock, par value		$ 0.001
Common stock, shares issued		69,115,849
Common stock, shares outstanding		69,115,849
Number of common stock issued upon the exercise of outstanding warrants		98,614,387
Number of common stock sold securities	$ 20,000
Sale of stock price per shares	$ 0.30
Restricted common stock, shares	2
Subsequent Event [Member] | Warrant [Member]
Restricted common stock, shares	1
Warrant term	5 years
Warrants to purchase common stock	66,666
Warrant price per share	$ 0.20
Subsequent Event [Member] | Lender [Member]
Revolving inventory financing facility			$ 1,000,000

Subsequent Events - Summary of

Subsequent Events - Summary of Convertible Notes with Lenders (Details) - USD ($)	Nov. 14, 2019	Nov. 08, 2019	Oct. 29, 2019	Oct. 23, 2019	Oct. 16, 2019	Oct. 10, 2019	Oct. 03, 2019	Sep. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
Principal Amount								$ 815,217
Original Issue Discount								65,217
Gross Proceeds								$ 750,000
Warrant Exercise Price Per Share										$ 0.625
Subsequent Event [Member] | Convertible Notes [Member] | Lenders as Stockholders [Member]
Principal Amount	$ 206,522	$ 16,304	$ 27,174	$ 108,696		$ 27,174	$ 27,174
Original Issue Discount	16,522	1,304	2,174	8,696		2,174	2,174
Gross Proceeds	$ 190,000	$ 15,000	$ 25,000	$ 100,000		$ 25,000	$ 25,000
Note Conversion Price Per Share		$ 0.07	$ 0.12	$ 0.12		$ 0.12	$ 0.12
Number of Shares Underlying Warrants	680,000	30,000	250,000	250,000		50,000	50,000
Warrant Exercise Price Per Share		$ 0.07	$ 0.12	$ 0.15		$ 0.12	$ 0.12
Subsequent Event [Member] | Convertible Notes [Member] | Lenders as Stockholders [Member] | Minimum [Member]
Note Conversion Price Per Share	$ 0.07
Warrant Exercise Price Per Share	0.07
Subsequent Event [Member] | Convertible Notes [Member] | Lenders as Stockholders [Member] | Maximum [Member]
Note Conversion Price Per Share	0.12
Warrant Exercise Price Per Share	0.20
Subsequent Event [Member] | Convertible Notes [Member] | Lender [Member]
Principal Amount					$ 217,391
Original Issue Discount					17,391
Gross Proceeds					$ 200,000
Note Conversion Price Per Share	$ 0.12				$ 0.07
Number of Shares Underlying Warrants					400,000
Warrant Exercise Price Per Share					$ 0.07
Subsequent Event [Member] | Convertible Notes [Member] | Lenders as Stockholders [Member]
Principal Amount				$ 108,696
Original Issue Discount				8,696
Gross Proceeds				$ 100,000
Note Conversion Price Per Share				$ 0.12
Number of Shares Underlying Warrants				250,000
Warrant Exercise Price Per Share				$ 0.20